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Abstract 
 
 
 KCNE β-subunits modulate KCNQ1 (Q1) voltage-gate K+ channels providing the 
current diversity required for Q1 channels to function in a wide variety of cell types and 
tissues.  In the present thesis, the stoichiometry of KCNE1 (E1) β-subunits in functioning 
Q1 channels is investigated, along with the formation of heteromeric channel complexes, 
complexes containing 2 different KCNE β-subunits.  The chemical approaches used to 
answer these questions were then expanded to generate a novel labeling reagent. 
 To determine the stoichiometry of the Q1/E1 complex, I devised an iterative 
subunit counting approach that relies on a chemically releasable K+ channel blocking 
reagent. The extracellularly applied reagent irreversibly blocks charybdotoxin (CTX) 
sensitive Q1 channels by chemically modifying E1 peptides that contain an N-terminal 
cysteine residue. Chemical release of the inhibitor and subsequent iterative applications 
of the reagent reported that Q1 channels partner with two KCNE β-subunits. 
 To determine whether heteromeric Q1-KCNE complexes form, I synthesized a 
similar, but non-cleavable, K+ channel blocking reagent that detects specific KCNE 
peptides in functioning complexes by irreversible channel inhibition. Using this “KCNE 
sensor”, heteromeric Q1/E1/E3, Q1/E1/E4 and Q1/E3/E4 complexes were shown to form, 
traffic to the cell surface and function. Using mathematical subtraction to visualize the 
irreversibly blocked current, the currents and gating kinetics of the different heteromeric 
complexes were revealed and a hierarchy of KCNE subunit modulation of Q1 channels 
was determined: E3>E1>>E4. 
 vi 
 Building on this technology, a chemically releasable K+ channel blocking reagent 
was created to specifically label KCNE β-subunits with biotin.  The reagent delivers 
biotin to CTX sensitive Q1 channels and labeling occurs through free thiols provided by 
either cysteine residues or thiol modified sugars.  This preliminary data demonstrates a 
novel strategy for labeling endogenous K+ channels in native cells. 
 vii 
Table of Contents 
 
 
 
Signature page ............................................................................................................. ii 
Dedication .................................................................................................................. iii 
Acknowledgements .................................................................................................... iv 
Abstract ........................................................................................................................v 
Table of Contents ...................................................................................................... vii 
List of Tables.............................................................................................................. ix 
List of Figures ..............................................................................................................x 
List of Symbols and Abbreviations ........................................................................... xiii 
Preface ......................................................................................................................xiv 
 
 
CHAPTER I: Introduction and Literature Survey..........................................................1 
 
Introduction .................................................................................................................1 
KCNQ1 K+ Channels...................................................................................................5 
Partnering KCNE β-subunits .......................................................................................6 
Shaker K+ Channels...................................................................................................12 
 Peptide Toxins to Probe Channels..............................................................................13 
Tethered Blockers......................................................................................................14 
Cellular Glycosylation ...............................................................................................17 
Outline of Thesis .......................................................................................................18 
 
 
CHAPTER II: Counting Membrane-Embedded β-subunits in Functioning K+ Channel 
Complexes...............................................................................................................21 
 
Abstract .....................................................................................................................21 
Introduction ...............................................................................................................23 
Material and Methods ................................................................................................26 
Binomial Analysis of MAL-ES Modification.............................................................32 
Results.......................................................................................................................34 
Discussion .................................................................................................................48 
 
 
 
 
 
 
 
 viii 
CHAPTER III: A Derivatized Scorpion Toxin Reveals the Functional Output of 
Heteromeric KCNQ1–KCNE K+ Channel Complexes..............................................53 
 
Abstract .....................................................................................................................53 
Introduction ...............................................................................................................54 
Materials and Methods...............................................................................................56 
Results.......................................................................................................................61 
Discussion .................................................................................................................74 
 
 
CHAPTER IV:  Toxin-directed labeling of K+ channel α- and β-subunits in native cells
................................................................................................................................78 
 
Abstract .....................................................................................................................78 
Introduction ...............................................................................................................79 
Material and Methods ................................................................................................83 
Results.......................................................................................................................92 
Discussion ...............................................................................................................106 
 
 
Chapter V: Future Directions ....................................................................................109 
 
 
Bibliography.............................................................................................................113 
 
 ix 
List of Tables 
 
 
Table II—1.    Recovery parameters of Q1/E1 complexes after application of derivatized 
CTX and non-derivatized CTX 
 
Table IV—1.  Recovery parameter of Q1/E1 and Shaker channels after CTX-Clv-Biotin 
application   
 x 
List of Figures  
 
 
 
 
 
Figure I-1.   (a) Topology diagram of a Kv channel (top) and High resolution structure of 
K+ channel Kv2.1 paddle chimera channel (PDB: 2R9R) (bottom).  (b) K+ 
ion location and GYG spacing 
 
Figure I-2.  TEVC recordings of Q1 and Q1/KCNE Channels 
 
Figure I-3.  Tethered blockers and inhibitors of K+ channel function 
 
Figure I-4.  Free thiol incorporation into glycoslylated cell surface protein  
 
Figure II-1.   A cartoon depiction of one modification cycle of the iterative counting 
strategy used to determine the number of KCNE1 subunits in a KCNQ1 K+ 
channel complex using a derivatized charybdotoxin (CTX). 
 
Figure II-2.  CTX-Clv electrospray mass spectrum (positive mode). 
 
Figure II-3.  Structures of the CTX-Clv reagent and TCEP cleavage of bis(N-
phenylcarbamoyl)disulfane linkers and the resultant products 
 
Figure II-4.  Retro synthesis of cleavable bismaleimide (2.3) 
 
Figure II-5.  Synthesis of CTX-Clv 
 
Figure II-6.  Characterization of CTX-Clv 
 
 xi 
Figure II-7.   Expression of exogenous KCNE peptides in Xenopus oocytes results in 
assembly with endogenous Q1 channels and measurable cell surface 
expression. 
 
Figure II-8.   CTX-Mal reagent is resistant to TCEP cleavage  
 
Figure II-9.   KCNQ1 K+ channel complexes contain 2 KCNE1 peptides. 
 
Figure II-10.  Only one KCNE peptide reacts per CTX-Clv treatment. 
 
Figure III-1.   CTX-Mal electrospray mass spectrum (positive mode) 
 
Figure III-2.   Co-expression of KCNQ1 channels with two different KCNE peptides 
gives rise to an amalgam of voltage-dependent and -independent currents. 
 
Figure III-3.   Cartoon depiction of the toxin tethering reaction between CTX-Mal and a 
cysteine residue in E1 and CTX-Mal reagent synthesis. 
 
Figure III-4.   Characterization of CTX-Mal on Q1/KCNE channels   
 
Figure III-5.   Detection of heteromeric Q1/E1/E3 complexes with CTX-Mal 
 
Figure III-6.    Detection of heteromeric Q1/E1/E3 complexes with CTX-Mal assaying 
Q1/E1/E3 (using native cysteine (C31) in E3) 
 
Figure III-7.   E4 peptides form heteromeric complexes with Q1 and E1. 
 
Figure III-8.  Current voltage analysis of Q1/E1 currents v. Q1/E1/E4 complexes 
 
 xii 
Figure III-9.   KCNE4 peptides form heteromeric complexes with KCNQ1 and KCNE3.    
 
Figure IV-1.   Structure of 1,3,4,6-tetra-O-acetyl-2-acetylthioacetamido-2-deoxy-a-D-
mannopyranose 4.1 (Ac5ManNTGc) and metabolic labeling of N-
glycoslylated cell surface proteins. 
 
Figure IV-2   Ac5ManNTGc electrospray mass spectrum (positive mode). 
 
Figure IV-3   CTX-Clv-Biotin electrospray mass spectrum (positive mode). 
 
Figure IV-4.  Synthesis of compound 4.4 
 
Figure IV-5.  Chemical synthesis of compound 4.6 
 
Figure IV-6.  Structure of Clv-Biotin 4.6 and synthesis of CTX-Clv-Biotin 
 
Figure IV-7.  Characterization of CTX-Clv-Biotin on KCNQ1/KCNE complexes  
 
Figure IV-8.  Characterization of CTX-Clv-Biotin on Shaker channels 
 
Figure IV-9.   Q1/E1WT complexes are irreversibly blocked by CTX-Mal when fed 
thiolated sialic acid, Q1 only channels are reversibly blocked.  
 
Figure IV-10.  Shaker channels are irreversibly blocked by CTX-Mal when fed   
acetylated thiol-ManNAc. 
 xiii 
List of Symbols and Abbreviations 
 
α   Alpha 
β   Beta 
Ac5ManNTGc 1,3,4,6-tetra-O-acetyl-2-acetylthioacetamido-2-deoxy-α-D-   
mannopyranose 
BM[PEO]3  Bismaleimide-3(polyethylene glycol) 
CHO   Chinese hamster ovary  
Clv   Cleavable linker 
CTX   Charybdotoxin 
CTX-Clv   Charybdotoxin cleavable-linker maleimide construct 
CTX-Lclv-Biotin Charybdotoxin cleavable-linker maleimide biotin construct 
CTX-MTSET Charybdotoxin 2-(trimethylammonium)ethyl]methane 
thiosulfonate bromide 
Dts   dithiasuccinyl 
E1, E3, E4, E5 KCNE1, KCNE3, KCNE4, KCNE5 
ER   Endoplasmic reticulum  
ESI    Electrospray ionization 
FRET   Fluorescence energy transfer 
HA   hemagglutinin-tagged  
HRMS   High resonance mass spectrometry 
HRP   Horse radish peroxidase 
IKs   Slow cardiac potassium current 
K+   potassium 
LPA   leupeptin, pepstatin and aprotinin 
Mal-ES   maleimide ethylsulfonate 
ManNAc  N-acetyl-D-mannosamine 
MTSET  2-(trimethylammonium)ethyl]methane thiosulfonate bromide  
N-linked  Asparagine linked 
PMSF   phenylmethylsulfonyl fluoride  
Q1   KCNQ1 
Q1*   charybdotoxin sensitive KCNQ1 channel  
Q1/E1    KCNQ1/KCNE1 complex 
TCEP   Tris(2-carboxyethyl)phosphine 
TEVC   Two-electrode-voltage-clamp  
UTRs   Untranslated regions 
VSD   Voltage sensing domain   
   
     
 
Standard one or three letter code was used to abbreviate amino acids.  Mutated residue 
abbreviated by position number.  Chemical compounds or formulas are abbreviated with 
standard periodic chart abbreviations for elements. 
 xiv 
 
 
 
Preface 
 
References to publications that represent the work contained within the thesis: 
 
Morin, T. M. and W. R. Kobertz (2007). "A Derivatized Scorpion Toxin Reveals the 
Functional Output of Heteromeric KCNQ1-KCNE K+ Channel Complexes." ACS Chem. 
Biol. 2(7): 469-473. 
 
Morin, T. M. and W. R. Kobertz (2008). "Counting Membrane-Embedded KCNE β-
subunits in Functioning K+ Channel Complexes." Proc. Natl. Acad. Sci. USA 105: 1478-
1482. 
 
Morin, T. M. and W. R. Kobertz (2008). "Tethering Chemistry and K+ Channels." J. Biol. 
Chem. (in press). 
 
 
Chemicals not directly generated by the author: 
 
William Kobertz synthesized the cleavable linker (Clv) and generated figures 1-1 and 1-2.  
Zhengmao Hua synthesized the Biotin-maleimide linker (Clv-Biotin). 
 
Figure not generated by author: 
 
Figure I-1b was originally published by João H. Morais-Cabral, Yufeng Zhou and 
Roderick MacKinnon, Nature 414, 37-42(1 November 2001)
 1 
CHAPTER I: Introduction and Literature Survey 
 
 
Introduction 
 
Voltage-gated K+ channels are multi-subunit integral membrane proteins that 
allow the passive diffusion of K+ ions down their electrochemical gradient.  Although the 
ultimate task of these channels, creating an aqueous hole in the membrane through which 
K+ ions may pass, seems inconsequential, the physiological relevance is enormous;  K+ 
channels are responsible for governing neuronal excitability, maintaining cardiac 
rhythmicity, and establishing the resting potential and epithelial electrolyte homeostasis 
in a wide variety of tissues (Robbins, 2001; Bezanilla, 2006). 
Voltage-gated K+ channels contain three essential components, a discriminating 
selectivity filter (or pore) through which K+, but not other ions pass, a voltage sensing 
domain (VSD), and an intracellular gate formed by intracellular C-terminal helices (the 
helix bundle crossing) that can impede or permit the flow of ions through the channel 
(figure I-1a) (Bezanilla, 2006).  A change in the intracellular membrane potential causes 
movement in the VSD resulting in a conformational change within the protein allowing 
the intracellular gate to open and permit K+ ions to flow down their concentration 
gradient near the rate of diffusion.  The ability of these channels to selectively pass K+ is 
due to the spacing and sequence (Glycine-Tyrosine-Glycine) of backbone carbonyl atoms 
in the pore region of the channel that energetically stabilize K+ ions and exclude other 
ions of similar size and charge (figure I-1b).  This means of K+ ion selection was  
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Figure I-1a.   Topology diagram of a Kv channel (top) and High resolution structure 
of K+ channel Kv2.1 paddle chimera channel (PDB: 2R9R) (bottom) 
 
 
(top)  The figure shows the voltage sensing domain S1-S4 (red), S4 contains arginine 
residues giving it a net positive charge.  The pore forming domain S5-S6 (blue) contains 
the pore loop (P) and the GYG amino acid sequence is responsible for K+ selectivity.   
 
(bottom)  For clarity, the front and back subunits have been removed.  The figure shows 
the three essential components of a voltage-gate K+ channel, voltage sensing domain 
(red), cytoplasmic gate (blue) and the selective pore, which is formed by 4 selectivity 
filters (gray loops) when subunits are assembled into tetramers.   
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Figure I-1b.  Possible locations of K+ ions in the selectivity filter and importance of 
GYG backbone spacing.   
 
 
(left)  Ribbon representation of the KcsA channel with the subunit closest to the viewer 
removed. Potassium ions (green spheres) bind at four locations in the selectivity filter 
(yellow) and in the water-filled cavity at the membrane centre (bottom ion).  
 
(right)  Close-up view of the selectivity filter in ball-and-stick representation, with the 
front and back subunits removed. The four K+ ions are numbered to indicate the location 
of binding sites in the filter; position 1 is closest to the extracellular solution and position 
4 is closest to the cavity. Key amino acids forming the selectivity filter are shown. 
Pictures were originally published by João H. Morais-Cabral, Yufeng Zhou and Roderick 
MacKinnon, Nature 414, 37-42(1 November 2001)
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 visualized after the first voltage-gated K+ channel was crystallized (Doyle et al., 1998; 
Cordero-Morales, 2006).  More recent bacterial and mammalian K+ channel crystal 
structures have assisted in the difficult task of assigning the exact position of the integral 
membrane segments and how their movements translate into opening and closing the 
channel (Doyle et al., 1998; Long et al., 2005a). High resolution crystal structures of 
voltage-gated mammalian K+ channels and molecular dynamic simulations reveal 
channel closing may occur through a ratcheting mechanism with the S4-S5 linker pushing 
down on the helix bundle crossing closing the intracellular gate.  Still hotly debated is the 
precise trajectory and displacement of the S4 segment in these voltage-gated channels 
during opening and closing conformational changes (Long et al., 2005a). 
Diversifying K+ channel architecture is the existence of accessory (orβ) subunits 
that partner with the ion conducting (or α) subunits.  Although it’s clear these β-subunits 
have a tremendous influence over channel function and modulation, very basic questions 
about them remain.  This thesis sought to answer two structural questions surrounding 
KCNQ1 (Q1) K+ channels: 1) What is the stoichiometry of KCNE β-subunits in a 
functioning Q1/KCNE channel complex, and 2) can two different KCNE β-subunits 
partner with and modulate a functioning Q1 K+ channel?  The approach used to answer 
these questions was then expanded to specifically modify K+ channel α and β-subunits 
with biotin, creating a novel labeling method that will facilitate future investigations and 
characterization of K+ channel α/β subunit complexes in native tissues. 
 
 
 5 
KCNQ1 K+ Channels 
 
Tetrameric assembly of KCNQ1 (Q1) proteins creates voltage-gated K+ selective 
ion channels found in many tissues throughout the human body, including cardiac, 
digestive, reproductive, and circulatory.  As such, these channels are involved in a 
number of diverse functions, some of the best studied are their role in maintaining cardiac 
rhythmicity through repolarization of cardiac myocytes (Barhanin et al., 1996; 
Sanguinetti et al., 1996), auditory transduction by maintaining K+/water homeostasis in 
the inner ear (Pusch et al., 1998), and proper digestion by establishing the resting 
membrane potential in colonic crypt cells (Schroeder et al., 2000).  
Each Q1 monomer consists of 6 transmembrane spanning segments termed S1-S6, 
with S1-S4 creating the VSD, while S5-S6 form the pore domain and K+ selective filter 
upon tetrameric assembly (figure I-1a).  Upon a change in intracellular membrane 
potential relative to the extracellular potential from negative to more positive, the VSD 
undergoes a transition from its resting to active state, largely due to the electronic 
repulsion of positively charged arginine residues in the S4 segment (Larsson et al., 1996; 
Jiang et al., 2003; Long et al., 2005a, b).  This conformational change is coupled to the 
opening of the intracellular cytoplasmic gate, permitting K+ ions to flow down their 
electrochemical gradient, resulting in cellular repolarization.   
Q1 monomers only assemble with other Q1 monomers to form homotetrameric 
ion conducting channels, unlike other family members such as KCNQ2 and KCNQ3 that 
co-assemble to form a Q2/Q3 heteromeric channel (Wang et. al., 1998).  In addition, Q1 
channel activation kinetics is slow compared to their neuronal Q2/Q3 and Shaker 
 6 
counterparts.  Presumably this is because the S4 helix of Q1 channels has less positive 
charge than neuronal counterparts, which manifests itself in slower channel opening 
(Panaghie and Abbott, 2007).  Figure I-2 show depolarization families, as the channels 
are depolarized to greater potential the channels conducted greater amounts of current.  
Not all channels and channel complexes open and conduct equally at a respective 
voltages, hence individual channels have differing current-voltage relationships.  A 
detailed inspection of tail currents recorded in high external K+ concentrations reveals 
Q1 channels inactivate and thus exist in at least 3 states: closed ↔ open ↔ inactive.  
Although the transition from open to inactive is hard to observe in Q1 channels, 
inactivated to closed is readily observed as a  “hook” in the tail current, which is due to 
the channels passing from the inactive state to the open state about 10 times faster than 
the channels pass from the open state to the closed state (Figure I-2) (Pusch et al., 1998).   
Interestingly, to date Q1 channel currents have not been physiologically observed, but 
instead Q1 is always partnered with a KCNE modulatory β-subunit.  This subunit not 
only removes or conceals the channel’s inactive state, but also has a tremendous 
influence over channel gating kinetics and voltage dependence.  
 
 
Partnering KCNE β-subunits 
 
 
KCNQ1 channels assemble with all 5 KCNE (E1-E5) peptides (McCrossan and Abbott, 
2004), a promiscuous family of mostly α-helical (Rocheleau et al., 2006; Kang et al., 
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2008) type I (extracellular N-terminus, intracellular C-terminus) transmembrane β-
subunits that range between ~100-150 amino acids.  Surprisingly, given their simple 
structure and topology, KCNE peptides modulate the electrical output and provide Q1 
channels with the necessary current diversity to meet the various K+ requirements of Q1-
expressing tissues (McCrossan and Abbott, 2004). For example, the ability of E1 to 
modulate Q1 channels in the heart is strikingly different from the ability of E3 to create a 
Q1 K+ leak channel in the colon.  A family of voltage clamp recordings show Q1/E3 
complexes appear to open instantaneously, and as evident by the tails, close very quickly 
too, pass significant amounts of inward current, and are devoid of inactivation (figure I-2).  
Q1/E1 channels open and close very slowly, pass absolutely no inward current under 
physiological K+ concentrations, and are more responsive to change in depolarization 
voltages.  Oddly, currents do not plateau, meaning the channels do not reach equilibrium 
between closed and open despite incredibly long depolarizing pulses (~ 90 s) (figure I-2).  
Partnering with E4 or E5 creates a non-conducting complex at physiological voltages 
(figure I-2), while Q1/E2 channels are kinetically similar to Q1/E3 channels (Tinel et al., 
2000; Jespersen et al., 2005).  
It has been proposed that a triplet of amino acids within the transmembrane 
domain of E1 and E3 confers modulation specificity to Q1 channels, because swapping 
these three residues essentially converts the recipient KCNE into the donor (Melman et 
al., 2002).  However, these results are in contrast with earlier KCNE1 deletion studies, 
which demonstrated that a C-terminal region (highly conserved between E1 and E3) was 
 8 
 
 
 
 
 
 
 
 
 
 
 
Figure I-2.  TEVC recordings of Q1 and Q1/KCNE Channels 
 
Two-electrode voltage clamp recordings for Q1 and homomeric Q1-KCNE complexes.  
Currents were elicited by a family of command voltages from –100 to 60 mV at 20-mV 
increments and recorded in KD50 solution.  Arrow denotes the “hook tail” of Q1 
channels, which is absent in Q1/KCNE complexes.  Dashed line indicates zero current.  
Scale bars represent 1 µA (vertical axis) and 0.5 s (horizontal axis).   
current 
current 
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responsible for E1 modulation of Q1 (Takumi et al., 1991; Tapper and George, 2000). 
Work by Gage and Kobertz demonstrated that the E3 transmembrane domain is sufficient 
for assembly with and modulation of KCNQ1 channels and they suggested a bipartite 
model for Q1 modulation by E1 and E3 subunits.  In this model, the E3 transmembrane 
domain is active in modulation and overrides the C-terminus’ contribution to fast gating, 
whereas the E1 transmembrane domain is passive and reveals C-terminal modulation of 
Q1 channels (Takumi et al., 1991; Gage and Kobertz, 2004).   
Two recent papers investigated whether KCNE peptides affect the voltage sensor 
equilibrium in Q1/KCNE complexes.  Both used electrophysiological recordings and 
methanethiosulfonate (MTS) modification of state dependent cysteine residues to show 
E1 peptides do not slow the movement of S4 from the resting to active state.  Therefore, 
slowed Q1/E1 activation may be due to a slowly opening intracellular gate (Nakajo and 
Kubo, 2007; Rocheleau and Kobertz, 2008).  In addition, it was realized E3 shifts the 
voltage sensor equilibrium to favor the active state at hyperpolarizing potentials and thus 
uncouples S4 movement from the opening and closing of the cytoplasmic gate 
(Rocheleau and Kobertz, 2008). 
Genetic mutations in β-subunits that lead to compromised complex function and 
disease (predominantly Long QT syndrome) underscore the physiological importance of 
properly assembled α/β-complexes (Splawski et al., 2000; Tyson et al., 2000).  Long QT 
disease, which is literally a lengthening of the Q to T interval in an ECG recording, is 
characterized by a lengthening of the refractory period during the cardiac action potential, 
generally due to a delay in cellular repolarization.  Despite the obvious requirement for 
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an α/β-subunit partnerships, basic structural questions surrounding these partnering 
peptides are still debated: (1) What is the location of KCNE peptides in Q1 complexes 
(Wang et al., 1996; Tai and Goldstein, 1998; Tapper and George, 2001), (2) What is the 
KCNE stoichiometry (Tzounopoulos et al., 1995; Wang and Goldstein, 1995; Salata et al., 
1998; Wang et al., 1998; Chen et al., 2003), and (3) Can heteromeric complexes (i.e. a 
single Q1 channel with two different KCNE’s) spontaneously assemble and function? 
(Wu et al., 2006, Manderfield, 2008).   
The location of KCNE peptides relative to KCNQ1 channels has been debated.  
Some argue that it crosses the membrane at the channel periphery (Romey et al., 1997; 
Wang et al., 1996; Tapper and George, 2001) or traverses the S4 canal (Kurokawa et al., 
2001). Others contend that KCNE residues gain exposure in the outer pore vestibule 
(Wang et al., 1996), reside close to the ion conduction pathway near the selectivity filter 
(Tai and Goldstein, 1998), and influence the structure of the internal pore vestibule from 
an unknown distance (Sesti et al., 2000). Studies in which Q1 was partnered E1 cysteine 
mutants found externally applied cadmium could induce pore blockage, suggesting 
KCNEs reside in or near the ion-conduction pathway (Tai and Goldstein, 1998).  
The number of KCNE β-subunits in the K+ channel complex has been a long-
standing debate (Tzounopoulos et al., 1995; Wang and Goldstein, 1995; Salata et al., 
1998; Wang et al., 1998; Chen et al., 2003).  Using charybdotoxin binding experiments 
and chimeric complexes, Goldstein and co-workers have strongly argued that Q1 
channels average 2 KCNE peptides per complex; however, they could not definitively 
rule out K+ channel complexes containing a solitary KCNE peptide (Chen et al., 2003).  
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Q1 modulation is altered when greater and greater amounts of KCNE1 are expressed, 
leading to the notion that Q1/E1 channels form complexes with KCNE β-subunits with 
multiple stoichiometries (Salata et al., 1998; Wang et al., 1998) .  The ensemble based 
approaches used in these studies measured the average number of KCNE peptides in the 
Q1 channel complex and therefore could not discern between fixed and mixed 
stoichiometries.  This thesis presents a chemical method for discerning KCNE 
stoichiometry in functioning KCNQ1 K+ complexes. 
The realization that multiple KCNE peptides are expressed in the same tissue has 
raised the possibility that two different KCNE subunits could assemble with the same K+ 
channel (Bendahhou et al., 2005; Lundquist et al., 2005; Lundquist et al., 2006).  mRNAs 
of all 5 KCNE peptides and isoforms were found in multiple regions of the heart and in 
many different tissues and organs in the mouse.  Equally surprising was that E4 was the 
most abundant KCNE transcript in the heart, a location where E1was assumed to far 
outnumber all others KCNE peptides to assure the physiologically required Q1/E1 
complex is free to form unfettered. The notion that a heteromeric channels can form was 
strengthened with co-immunoprecipitation of one KCNE peptide (E4) by another KCNE 
peptide (E1) (Wu et al., 2006; Manderfield, 2008).  However, these qualitative 
biochemical experiments were not definitive because it was unclear whether these 
precipitated complexes were functional. This thesis examines heteromeric channel 
formation and function using a chemical method. 
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Shaker K+ Channels 
 
Voltage-gated Shaker K+ channels are also formed by the tetrameric assembly of 
α-subunits that form a K+ selective aqueous pore (MacKinnon, 1991).  Like Q1 channels, 
each monomer contains 6 transmembrane spanning segments; again S1-S4 forms a 
voltage sensor, while S5-S6 forms the pore domain.  Unlike Q1, however, Shaker  has 
not been shown to partner with a modulatory membrane embedded β-subunit and is 
glycosylated (Santacruz-Toloza et al., 1994; de Souza and Simon, 2002; Khanna et al., 
2004). 
Shaker channels, which are native to the hippocampal neurons of Drosophila 
melanogastar (Salkoff, 1990), have proved exceedingly useful as a model for the study of 
all voltage-gated K+ channels.  This is due to their ability to provide very robust and 
stable currents in a number of expression systems, amphibian to mammalian, and comply 
with a number of electrophysiological techniques, including two-electrode voltage clamp 
(TEVC) and single channel recordings.     
Chapter IV of this thesis uses Shaker-inactivation removed (Shaker-IR) channels 
as a model to show that chemical tethering and labeling is not restricted to Q1 β-subunits 
(KCNE peptides).  The Q1 α-subunits can also be modified using introduced cysteines or 
thiol containing extracellular glycans.  Shaker-IR (herein referred to as simply Shaker) 
channels have a C-terminal domain removed that, when present, plugs the pore internally 
causing inactivation.  These Shaker-IR channels are also mutated at position 425 (425G) 
to confer charybdotoxin sensitivity.    
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Peptide Toxins to Probe Channels 
 
Studying channel complexes provides a unique set of challenges due to their 
membranous lipid environment.  Fortunately, nature has provided a wide range of toxins 
(e.g. scorpion, spider, and snail) that selectively target subtypes of K+ ion channels.  
Using various toxins it has been possible to determine α-subunit stoichiometry of K+ 
channels (MacKinnon, 1991), map the outer channel vestibule (MacKinnon et al., 1998), 
improve our understanding of the roles played by individual channel types (Inglis et. al., 
2003; Yoshida and Matsumoto, 2005) and aid in the synthesis of therapeutic compounds 
to target particular classes of potassium channels (Talley et. al, 2006). 
Determining residues advantageous or deleterious to toxin binding has allowed 
toxin sensitivity to be engineered into previously insensitive channels (Goldstein et al., 
1994).  This technique was used to confer charybdotoxin (CTX) sensitivity on Q1 
channels after studying CTX’s interaction with its native targets, the big conductance K+ 
(BK) and Shaker family channels (Smith et al., 1986; Goldstein et al., 1994; Chen et al., 
2003).  Furthermore, mapping studies along with NMR structural data has allowed non-
native cysteines to be engineered into these cysteine rich toxins providing a reactive 
handle onto which different chemical moieties may be attached (Shimony et al., 1994; 
Posson et al., 2005; Yu et al., 2005).  CTX is a 39 amino acid extremely stable globular 
peptide, due to 3 internal disulfide bridges, and binds to modified Q1 channels slightly 
off center of the pore with a 1:1 stoichiometry.  The work presented here takes advantage, 
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of Q1 channels with engineered charybdotoxin sensitivity (Q1*) and a cysteine modified 
charybdotoxin (R19C). 
 
Tethered blockers  
 
 Tethered blockers are chemical reagents comprised of an ion channel inhibitor or 
pore blocker linked to a reactive functional group.  These bifunctional molecules typically 
act as affinity labeling reagents—binding first to the ion channel and then reacting with the 
target protein residue.  For example, a channel blocker linked to a thiol reactive moiety can 
accelerate the kinetics of thiol modification 1000-fold by increasing the local concentration 
of the reactive group near the free thiol (Blaustein et al., 2000).   
Blaustein and colleagues used tethered blockers to measure the distances from the 
extracellular segments of the K+ channel voltage sensor to the external 
tetraethylammonium blocking site at the entrance of the pore (Blaustein et al., 2000). By 
synthesizing a panel of quaternary ammoniums (QA) linked to maleimides with varying 
length polyglycine tethers (Figure I-3), they could systematically find a tether that was 
just long enough to block the channel. The KcsA crystal structure (Doyle et al., 1998) 
was then used to calibrate the distances measured with the different-length tethered 
blockers.  These blockers in combination with electrophysiology revealed that the top of 
the S3 segment is the farthest away from the center of the Shaker K+ channel followed 
closely by the S1 segment, and the extended S3-S4 loop is the closest (Blaustein, 2002).  
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In addition to the ability of tethered blockers to report on K+ channel architecture, 
a K+ channel tethered blocker with a light-activatable linker was used to control K+ 
channel function in neurons.  A photoswitchable reagent, composed of a maleimide linked 
to a quaternary amine through a spacer that adopts an extended trans configuration in 
visible light, or a condensed cis conformation under UV light, was used to turn modified 
Shaker channels “on” or “off” by blocking or unblocking channels (Banghart et al., 2004; 
Volgraf et al., 2006).  The straightforward approach and modularity of the tethered 
blocker technology was utilized in this thesis.  
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Figure I-3.  Tethered blockers and inhibitors of K+ channel function 
 
(top)  Kv channel modified with quaternary ammonium tethered blockers. The linker on 
the tethered blocker on the left voltage sensor is long enough to allow the QA to reach its 
binding site and block conduction whereas the tethered blocker on the right voltage 
sensor is too short and the conductance of the channel is unaffected. (middle) Chemical 
structures of tethered blockers. The effective tether length can be adjusted by 
incorporating glycine residues using standard solid phase peptide synthesis. Gly(0): 21 Å; 
Gly(7): 45 Å. (bottom)  A photoisomerizable azobenzene linker that changes its effective 
length by ~ 7 Å upon exposure to different wavelengths of light. 
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Cellular Glycosylation 
 
Many K+ channels destined for the cell surface are initially N-linked glycoslylated 
in the rough endoplasmic reticulum (ER), a process involving the covalent attachment of 
a branched saccharide chain to the amide nitrogen of asparagine side chains while the 
peptide is being synthesized (co-translational) or after the entire protein is synthesized 
(post-translational). 
N-linked glycosylation occurs at N/X/T or S sequence motifs (where N is an 
asparagine residue, X is any amino acid but proline and T or S is a threonine or serine) 
and is important for efficient folding and trafficking of proteins to the cell surface 
(Santacruz-Toloza et al., 1994; Khanna et al., 2001; de Souza and Simon, 2002).  The 
glycosylation process starts with the enzymatic addition of a 14-sugar precursor made up 
of 3 glucose, 9 mannose, and 2 N-acetylglucosamine (ManNAc) molecules, after 
oligosaccharide attachment and proper protein folding, the three terminal glucose 
residues are removed from the chain and the protein is exported from the ER to the Golgi.   
In the Golgi, further mannose trimming, addition of N-acetylglucosamine and 3-5 
terminal sialic acid sugars results in a mature oligosaccharide signaling the glycosylation 
process is complete, and the protein is trafficked to the cell surface or final intracellular 
destination (Helenius and Aebi, 2001). 
It was realized that mammalian cells grown with media containing non-natural 
thiol-containing ManNAc (a sialic acid precursor) will take up the modified sugar and 
incorporate it into the mature form of a glycan as the terminal sugar (Yarema et al., 1998; 
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Dube and Bertozzi, 2003).  This allows all sialic acid containing cell surface proteins to 
have an accessible extracellular reactive thiol that can be used for various types of 
tethering chemistries (figure I-4).  In addition to reactive thiols, azides or nucleophiles 
can be incorporated into the non-natural sugar providing an even more diverse array of 
chemical handles on the cell surface, thus allowing tethering chemistries with alkynes or 
electrophiles to be used (Laughlin and Bertozzi, 2007).  This thesis explored possible 
ways to label endogenous channels in native cells types or tissues using these modified 
sugar moieties. 
 
 
Outline of Thesis 
 
The objective of this thesis was to 1) determine the stoichiometry of KCNE1 β-
subunits in a functioning KCNQ1/KCNE1 complex, 2) determine whether two different 
KCNE β-subunits can partner with and modulate a single KCNQ1 channel, and 3) 
develop new cell surface labeling technologies using N-linked glycosylated proteins. 
Chapter II described the synthesis and utilization of a chemically reversible Q1 
channel blocker that, in combination with two-electrode voltage-clamp (TEVC) 
recordings of Xenopus oocytes, allowed the β-subunit stoichiometry of functioning 
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Figure I-4.  Free thiol incorporation into glycosylated cell surface protein  
Mammalian cells can be fed non-natural sugar precursors that contain aceylated thiols.  
Cellular machinery will remove the acetyl groups and incorporate the sugar into a glycan 
destined to be extracellular resulting in the cell surface expression of a reactive thiolate 
handle.    
Plate of cells 
Feed cell  
non-natural sugar 
SH SH 
SH SH SH SH 
N-linked glycosylated cell surface proteins 
express reactive thiols 
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Q1/E1 complexes to be determined.  It was found that the Q1/E1 ratio is fixed and there 
are two KCNE1 β-subunits in a fully assembled Q1/E1 channel complex.   
Chapter III describes the experiments used to determine whether a single Q1 
channel can partner with two different KCNE β-subunits and still pass current.  This was 
accomplished by using TEVC recordings and a derivatized scorpion toxin that 
irreversibly inhibits Q1 K+ channel complexes that contain a specific KCNE peptide.  I 
found Q1/E1/E4, Q1/E1/E3, and Q1/E3/E4 complexes assemble and are functional.   
Furthermore, mathematical subtraction of currents allowed the visualization of currents 
generated from functioning heteromers and a hierarchy of KCNE peptide modulation of 
Q1 channels was proposed, E3>E1>>E4. 
Chapter IV describes the synthesis and use of a reagent that is able to specifically 
label Shaker α-subunits or E1 β-subunits in functioning Q1 channels with biotin.  TEVC 
recordings suggested biotin labeling present on the E1 peptide and Shaker channels.  
Repeating the experiments using cells grown with non-natural thiol-containing ManNAc 
sugars demonstrated a novel way to label native K+ channel α- and β-subunits. 
I collaborated with Zhengmao Hua, post-doctoral researcher in the Kobertz lab, to 
complete the work in Chapter IV.  He synthesized the non-natural ManNAc sugar and a 
cleavable linker conjugated to biotin. 
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CHAPTER II: Counting Membrane-Embedded β-subunits in 
Functioning K+ Channel Complexes 
 
 
Abstract 
 
Ion channels are multi-subunit proteins responsible for the generation and 
propagation of action potentials in nerve, muscle and heart as well as maintaining salt and 
water homeostasis in epithelium.  The subunit composition and stoichiometry of these 
membrane protein complexes underlies their physiological function, as different cells pair 
up ion conducting α-subunits with specific regulatory β-subunits to produce complexes 
with diverse ion conducting and gating properties. However, determining the number of 
β-subunits in functioning ion channel complexes has been challenging and fraught with 
contradictory results.   
This chapter describes the synthesis of a chemically-releasable, irreversible K+ 
channel inhibitor and its iterative application to tally the number of β-subunits in a Q1/E1 
K+ channel complex where the stoichiometry of the complex is still debated.  Using this 
inhibitor in TEVC electrical recordings, it was determined there are two KCNE subunits 
in a functioning tetrameric K+ channel, breaking the apparent four-fold symmetry of the 
ion conducting pore.  This digital determination rules out all other supra, sub and multiple 
stoichiometries, providing a uniform structural picture to interpret KCNE β-subunit 
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modulation of voltage-gated K+ channels and the inherited mutations that cause 
dysfunction.  Moreover, the architectural asymmetry of the K+ channel complex affords a 
unique opportunity to therapeutically target ion channels that co-assemble with KCNE β-
subunits.  Given the wide assortment of specific ion channel inhibitors, this approach can 
be adapted to identify and enumerate the protein subunits in other multimeric ion channel 
complexes. 
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Introduction 
 
Voltage-gated KCNQ1 K+ channels are tetrameric integral membrane proteins 
that open and close in response to changes in membrane potential.  To regulate cellular 
potassium flow in both excitable and non-excitable tissues, Q1 channels co-assemble 
with regulatory KCNE peptides, forming membrane-embedded K+ channel complexes 
with different voltage-sensing and gating properties (McCrossan and Abbott, 2004).   
Although the four-fold arrangement of the Q1 α-subunits along the ion 
conduction pathway is established and unquestioned, the number of KCNE β-subunits in 
the K+ channel complex has not been definitively determined (Tzounopoulos et al., 1995; 
Wang and Goldstein, 1995; Wang et al., 1998; Chen et al., 2003).  To determine the 
stoichiometry of a Q1-KCNE K+ channel complex, an iterative cell surface modification 
scheme was devised where the labeling reagent specifically binds to the outer vestibule of 
the K+ conduction pore while covalently modifying a cysteine-bearing KCNE peptide in 
the channel complex (Figure II-1).  Once the reaction is complete, excess reagent is 
removed and the covalently bound toxin is chemically released, restoring K+ channel 
complex function.  However, the reactive cysteine  in one KCNE peptide is irreversibly 
modified.  Thus, the number of KCNE peptides in the K+ channel complex is simply the 
number of complete modification cycles (reagent in, out, cleaved) required before the 
toxin binding becomes reversible. 
For the outlined counting strategy to be operational, there are two absolute, but 
experimentally testable conditions: (1) the non-specific bimolecular reaction between  
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Figure II-1    A cartoon depiction of one modification cycle of the iterative counting 
strategy used to determine the number of KCNE1 subunits in a KCNQ1 K+ channel 
complex using a derivatized charybdotoxin (CTX). 
 
Starting with an unmodified channel complex (figure middle left) reagent is added 
(orange) and allowed to irreversibly block channels through maleimide-thiol tethering.  
After linker cleavage (middle right) the CTX blocking moiety is free to diffuse away, and 
E1 subunits are permanently modified (figure bottom middle).  Each complete round of 
chemical treatment modifies one E1 subunit, allowing for the direct counting of KCNE 
subunits in the K+ channel complex. 
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the reagent and the cysteine in the KCNE peptide must not occur.  (2) Only one KCNE 
peptide in the K+ channel complex may react during the exposure to the reagent. 
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Material and Methods 
 
 
Mutagenesis and In Vitro Transcription:   
For optimal CTX binding to the Q1/E1 complex, CTX sensitive Q1 and hemagglutinin-
tagged E1 constructs between residues 11 and 12 were used and subcloned into a vector 
containing the 5’ and 3’ UTRs from the Xenopus β-globin gene for optimal expression in 
Xenopus oocytes.  Site-directed mutagenesis was performed using Quickchange 
(Stratagene).  mRNA in vitro transcription was performed by linearizing plasmid DNA 
with Mlu I (NEB) and run-off transcription with SP6 RNA polymerase (Promega) .  
 
Oocyte preparation and cRNA injection:  
Mature oocytes were surgically extracted from anesthetized Xenopus laevis.  Isolated 
oocytes were mechanically separated and bathed in OR2 (mM):  82.5 NaCl, 2.5 KCl, 1 
MgCl2, 5 HEPES, pH 7.4 + 2 mg/ml collagenase (Worthington Biochemical Corp.) for 
85-95 minutes to remove ovarian material and follicles.  After rinsing, oocytes were 
incubated overnight at 18°C in ND96-bathing (ND96B) solution + gentamicin + 
glutathione (mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 50 µg/ml gentamicin 
(Sigma), 2 mM glutathione (Sigma), pH 7.4.  For TEVC, oocytes were injected with a 
Q1:E1 mRNA ratio (15:5 ng) to ensure that E1 was in excess.  Oocytes were incubated 
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for 3–5 days with 3 mM L-glutathione, pre-treated with 1 mM TCEP for 15 min before 
recording, 
 
Electrophysiology 
Currents were measured using two-electrode voltage clamp (OC-725-C, Warner 
Instrument Corp.) and data acquired with Digidata 1322A (Axon Instruments) running 
Clampex 8.2 (Axon Instruments) at RT.  Electrodes were filled with 3M KCl, 5 mM 
EGTA, 10 mM HEPES, pH 7.6, and had resistance between 0.2 – 1.5 MΩ.  A home-
made gravity-fed perfusion chamber was used, in which complete solution exchange 
occurred within ~ 10 s.  ND96 (mM):  96 NaCl, 2 KCl, 0.3 CaCl2, 1 MgCl2, 5 HEPES, 
pH 7.0.  The current was measured by holding at – 80 mV and pulsing to +20 mV for 5 s 
every 30 s in ND96.  
 
Cell Surface Chemistries: 
Labeling reagents CTX-Clv and CTX-Mal (10 nM) were in ND96 solution with 50 µg 
mL-1 bovine serum albumin and were added to the bath by a gravity-fed perfusion system 
with a chamber clearing time of ~ 10 s. CTX-Clv cleavage was accomplished by 1 mM 
TCEP for ~180 s.  To randomly label cell surface cysteines with Mal-ES (Lu et al., 
2007), TCEP-pretreated oocytes were incubated with 10 µM Mal-ES in ND96 for 500 s.   
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Chemical Synthesis: 
 
3-maleimido-N-[2-(phenylamino)ethyl]propanamide (2.1) was synthesized by 
dissolving 1.33 g (5 mmol) of 3-Maleimidopropionic acid N-hydroxysuccinimide ester 
(Aldrich) in 100 mL of methylene chloride.  N-phenylethylenediamine (0.72 mL, 5.5 
mmol) and triethylamine (0.78 mL, 5.5 mmol) were added and the solution turned yellow 
and a white precipitate formed.  After 4 hours at room temperature, the precipitate was 
filtered and the solvents were removed in vacuo to afford a yellowish-orange oil.  The 
crude material was purified by silica gel chromatography eluting with a gradient of 20:1 
to 10:1 methylene chloride:ethyl acetate to yield 0.83 g (58%).  1H NMR (400 MHz, 
CDCl3) δ 2.53 (app t, 2 H, J = 7.0), 3.24–3.27 (m, 2 H), 3.47–3.51 (m, 2 H), 3.84 (app t, 2 
H, J = 7.0), 6.61 (d, 2 H, J = 8.5), 6.62 (s, 2 H), 6.71 (t, 1 H, J = 7.3), 7.18 (t, 2 H, J = 
8.5); 13C NMR (100 MHz, CDCl3) δ 34.26, 34.80, 39.00, 43.64, 112.7, 117.5, 129.3, 
134.1, 147.9, 170.4, 170.6; HRMS (ESI) calculated for C15H17O3N3 (M+H)+  equals 
288.1348, experimentally found was 288.1. 
 
Bis(chlorocarbonyl)disulfane (2.2) was synthesized via literature precedent (Barany et 
al., 1983; Martinez and Vega, 1986) with several modifications to simplify the procedure 
for small scale preparations.  Ethoxythiocarbonyl chloride was synthesized as previously 
described (Martinez and Vega, 1986) and used without distillation.  An equimolar (5 
mmol) amount of chlorocarbonylsulfenyl chloride (Alfa Aesar) was added to neat 
ethoxythiocarbonyl chloride (5 mmol) and the reaction was allowed to stir overnight at 
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room temperature.  The reaction was chilled to 0°C with an ice bath, a catalytic amount 
of FeCl3 (~1 g) was added, and the reaction warmed slowly to room temperature 
overnight.  The low boiling contaminants were removed by rotary evaporation at 
aspirator pressure and then the product was purified by distillation and characterized by 
NMR as previously described (Barany et al., 1983). 
 
Cleavable bismaleimide (2.3).  A solution of 0.83 g (2.9 mmol) of compound 2.1 in dry 
chloroform was chilled to – 20°C, and a solution of 175 µL (1.5 mmol) of 
bis(chlorocarbonyl)disulfane in 5 mL of chloroform was slowly added to this solution.  
The cooling bath was removed and the reaction was allowed to stir at room temperature 
for 1 hr.  The reaction was diluted with chloroform, washed twice with 0.1 N HCl, and 
the organic layer was dried over Na2SO4.  The solvents were removed in vacuo and the 
crude product was purified by silica gel chromatography eluting with a shallow gradient 
from CHCl3 to 33:1 CHCl3:methanol to afford 226 mg (23%).  1H NMR (400 MHz, 
CDCl3) δ 2.56 (app t, 4 H, J = 7.0), 3.44–3.48 (m, 4 H), 3.84–3.88 (m, 8 H), 6.62 (s, 4 H), 
7.37–7.46 (m, 10H); 13C NMR (100 MHz, methanol-d4 with 10% CDCl3) δ 33.26, 33.61, 
36.56, 50.06, 128.9 (br. s), 129.1, 133.5, 138.6, 164.8, 170.0, 170.8; Different NMR 
solvents were needed because of differing solubility’s of the compounds.  HRMS (ESI) 
calculated for C32H32O8N6S2 (M+H)+  693.1801, found 693.2. 
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Synthesis of CTX-Clv: 
Recombinant CTX R19C was purified and the protected CTX-MTSET adduct was 
prepared according to Shimony and Miller (Shimony et al., 1994).  CTX-Clv was 
synthesized as follows: 16 nmols of CTX-MTSET in 2 mL of low salt buffer: (mM) 10 
NaCl, 10 KPi, pH 7.4 was reduced with 1 mM DTT for 45 mins.  Reduced CTX was 
HPLC purified using a C18 column (4.6 mm x 250 mm) eluting with solvent A: 0.1% 
TFA; solvent B: acetonitrile; gradient 10 to 40% B over 30 min. The pH of the fraction 
containing reduced CTX was adjusted to pH 7.0 using 1 M KPi, pH 7.1, and a solution of 
16 µmol of bismaleimide 2.3 in 90 µl neat acetonitrile was slowly added and allowed to 
react for 30 min at room temperature. The reaction was placed on ice for 10 min to 
precipitate excess unreacted bismaleimide 2.3, which was removed by filtration (GHP 
Acrodisc 0.45 um, Pall Gelman Laboratory). CTX-Clv was desalted and HPLC purified 
using the column and solvents described above, using a 20 to 50% gradient B over 30 
min.  The concentration of purified CTX-Clv was determined by UV spectrometry 
(OD280 of 1.0 = 100 uM CTX) (Shimony et al., 1994) and labeling efficiency of CTX-
R19C was determined to be 30% ± 8% (n = 7).  The purified product was confirmed by 
ESI mass spectrometry (Figure II-2) and was aliquoted, lyophilized, and stored at – 20°C.  
Immediately prior to use, individual aliquots were resuspended in ND96 recording 
containing 30% acetonitrile to ensure CTX-Clv went into solution.  This solution was 
then diluted such that the final acetonitrile concentration was 0.3% and the final CTX-Clv 
concentration was 10 nM. 
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Figure II-2.   CTX-Clv electrospray mass spectrum (positive mode). 
 
Expected MW for CTX-Clv:  4933.0 (methionine oxidized); +3, 1646.0; +4, 1234; +5, 
988.  CTX-Clv: 5157 (methionine oxidized, 2 x TFA); +3, 1718.0; +4, 1289.5. 
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Binomial Analysis of MAL-ES Modification 
 
The distribution of modified KCNE–K+ channel complexes generated by a partial 
treatment of MAL-ES can be defined by the probability mass function if each 
modification occurs independently: 
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where n is the number of KCNE peptides, k is the number of modified KCNE peptides,  p 
is the probablility, and F is the fraction of K+ channel complexes with all KCNE peptides 
modified when k = n.  If one KCNE is modified per CTX-Clv treatment cycle, then 
Figure II-9 demands that there are two KCNE peptides in the complex.  Therefore, p = 
0.44 when k = 2, n = 2 and F = 0.19, which was experimentally determined after CTX-
Clv washout (Figure II-10).  The complementary cumulative distribution function 
predicts the reversibility in the second CTX-Clv washout. 
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where x is equal to the maximum number of MAL-ES modifications a K+ channel 
complex can have such that there is at least one modifiable cysteine remaining in the 
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second cycle.  For n = 2, x = 0 since all K+ channel complexes will have one CTX-Clv 
modification, which occurred during the measuring of F.  Thus, the expected reversibility 
for one CTX-Clv modification per cycle with two KCNE peptides in a K+ channel 
complex (x = 0; n = 2 and p =0.44) is R = 0.69.  Conversely, if two KCNE modifications 
occur per exposure to CTX-Clv, then each complex must have four KCNE peptides 
(Figure 4b) and p = 0.66 when k = 4, n = 4 and F = 0.19.  In this scenario, x = 1 for the 
cumulative distribution function since only complexes with less than two MAL-ES 
modifications will have a modifiable cysteine in the second round of treatment.  Thus, the 
expected reversibility for two CTX-Clv modifications per cycle with a 4 KCNE peptide–
K+ channel complex (x = 1; n = 4 and p =0.66) is R = 0.88.  Non-integer KCNE 
modifications per CTX-Clv exposure are not considered since we did not observe any 
partial modifications or irreversibility in any of the rounds of the treatment.  Integer 
modifications greater than two KCNE peptides are possible, however, these would result 
in R > 0.95 when F = 0.19. 
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Results 
 
Central to the counting strategy is the chemically-releasable irreversible K+ 
channel inhibitor.  This reagent, CTX-Clv, is composed of three functional groups:  (1) a 
high affinity K+ channel inhibitor tethered to (2) a cysteine-specific modifying agent via 
(3) a cleavable linker (Figure II-3 top).  For the K+ channel inhibitor, charybdotoxin 
(CTX) was chosen, a peptide scorpion toxin that tightly binds to the tetrameric ion 
conduction pore with 1:1 stoichiometry (Smith et al., 1986).  A maleimide was used for 
the cysteine-modifying agent since it forms an irreversible thioether bond with cysteines 
that is stable to reducing agents.  For the cleavable linker, we synthesized a homo-
bifunctional linker, which when cleaved with reductant does not reintroduce a thiol group.  
This is critical; reintroduction of a thiol would be detrimental because a complexed E1 
peptide would be capable of participating in more than one round of tethered block, thus 
influencing the counting results.  The linker was based on the cyclic dithiasuccinyl (Dts) 
amino protecting group (Barany and Merrifield, 1977).  The linear linker, bis(N-
phenylcarbamoyl)disulfane (figure II-3 top), is rapidly cleaved (< 2 min) with cell-
compatible reductants (dithiolthreitol, β-mercaptoethanol, and Tris(2-
carboxyethyl)phosphine (TCEP)) at biological pH, leaving behind secondary aryl amines 
with the concomitant release of two equivalents of carbonylsulfide gas (Figure II-3 
middle and bottom). 
To tether the maleimide to CTX, a cleavable bismaleimide 2.3 was synthesized.  
Commercially available 3-Maleimidopropionic acid N-hydroxysuccinimide ester was 
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reacted with N-phenylethyldiamine to afford 3-maleimido-N-[2-(phenylamino)ethyl] 
propanamide (2.1).  Compound 2.2 was synthesized via literature precedent (Barany et al., 
1983; Martinez and Vega, 1986).  Addition of bis(chlorocarbonyl)disulfane 2.2 to 2 
equivalents of maleimide 2.1 afforded the bismaleimide linker 2.3 in 25% yield after 
silica gel purification. 
CTX-Clv was then synthesized by adding excess 2.3 to purified CTX R19C 
(figure II-5 and Methods). CTX mutant R19C, which upon derivatization with cysteine-
modifying reagents has been shown to maintain its high affinity for the ion conduction 
pore of K+ channels (Shimony et al., 1994).  Briefly, the R19C mutated charybdotoxin 
was purified as a fusion protein with bacterial protein gene 9.  After one round of 
purification using anion exchange, the negatively charged gene 9 was trypsinized 
allowing HPLC purified positively charged CTX-R19C to be labeled with MTSET and 
further purified using cation exchange.  The mixed disulfide CTX-MTSET adduct was 
reduced, HPLC purified, and labeled with 500-fold molar excess 2.3 for 10 min.  Excess 
bismaleimide was precipitated, and the labeled toxin was HPLC purified.  Final CTX-Clv 
product was confirmed using ESI-MS (figure II-2).    
CTX-Clv was first subjected to a battery of experimental tests to assess whether it 
could meet the two requirements of the repetitive labeling strategy.  Since CTX does not 
bind to wild-type Q1 channels, we utilized a variant of Q1 (Q1*) that binds CTX with 
nanomolar affinity (Chen et al., 2003).  Q1/E1T14C complexes were expressed in Xenopus 
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Figure II-3  Structures of the CTX-Clv reagent and TCEP cleavage of bis(N-
phenylcarbamoyl)disulfane linkers and the resultant products. 
 
The three essential components of CTX-Clv are Q1* channel inhibiting CTX, cleavable 
disulfide linker and reactive maleimide (Top).  1 mM TCEP treatment cleaves CTX-Clv 
via disulfide reduction as shown (middle).  The 3 resulting products are modified CTX, a 
modified thiol reactive maleimide, and two carbonyl sulfide molecules released as a gas 
(Bottom). 
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oocytes and the CTX-sensitive current was monitored since background endogenous 
oocyte currents are not inhibited by CTX (Kobertz and Miller, 1999; Morin and Kobertz, 
2007).  In all experiments, only ~85% of the total current could be inhibited (reversibly 
or irreversibly); even in the presence of 250 nM wild-type CTX (figure II-6), which 
based on the calculated dissociation constant for CTX-sensitive Q1/E1 complexes should 
afford 99.9% inhibition (Chen et al., 2003).  We did not expect 100% block because 
Xenopus oocytes possess low levels of endogenous, CTX-insensitive Q1 channels that 
migrate to the cell surface with the injection of KCNE mRNAs (Figure II-7).  Figure II-6 
shows the normalized CTX-sensitive current elicited by a 20 mV pulse from an oocyte 
expressing Q1/E1T14C complexes.  Treatment with 10 nM CTX-Clv followed by washout 
resulted in complete, irreversible inhibition of the K+ channel complex in 3 min (Figure 
II-6a).  The rapid irreversible inhibition observed with CTX-Clv was expected based on 
previous affinity-driven modifying agents, which increase the reagent’s effective molarity 
thereby accelerating the chemical reaction (Blaustein et al., 2000).  Subsequent treatment 
with 1 mM TCEP for 2 min relieves the irreversible inhibition and restores the current to 
pre-treated levels.  Irreversible inhibition requires the cysteine in E1 since CTX-Clv is an 
entirely reversible inhibitor with wild type Q1/E1 complexes (Figure II-6b).  These 
results demonstrate that each step in the modification cycle occurs quantitatively within 
minutes. 
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Figure II-5.  Synthesis of CTX-Clv 
The mixed disulfide CTX-MTSET adduct was reduced with DTT, HPLC purified, and 
labeled with 500-fold excess 2.3 for 10 min., HPLC purified, aliquoted and stored dry.  
Final CTX-Clv product was confirmed using ESI-MS (figure II-2).    
2.3 
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To directly demonstrate the non-specific bimolecular reaction between CTX-Clv 
and E1T14C does not measurably occur, a competition experiment was performed in which 
Q1/E1T14C complexes were treated with 10 nM CTX-Clv and 500 nM of unlabeled CTX 
for an extended duration.  CTX-Clv did not modify the Q1/ E1T14C complex in the 
presence of excess competitor (unlabeled CTX), as evidenced by complete washout 
(Figure II-6c). 
To determine whether a covalently tethered CTX-Clv prevents further toxin-
accelerated modifications of the other KCNE peptides in the channel complex, a second 
competition experiment was performed, this time using CTX-Mal (detailed synthesis in 
Chapter III) (Figure II-6d), a non-cleavable version of CTX-Clv.  CTX-Mal irreversibly 
inhibits Q1/E1T14C with a similar modification rate to CTX-Clv (Morin and Kobertz, 
2007), yet the irreversible inhibition by CTX-Mal is completely resistant to TCEP 
treatment (Figure II-8b).  Q1/E1T14C complexes were first irreversibly inhibited by CTX-
Clv, as observed after washout (figure II-6d).  The inhibited complexes were then treated 
with CTX-Mal for the same duration and the reagent was washed out.  A final treatment 
with TCEP resulted in complete restoration of the current that was measured before the 
toxin treatment sequence began.  This sequence of treatments shows a covalently tethered 
CTX-Clv prevents further toxin-accelerated modifications of the other KCNE peptides in 
the channel complex. 
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Figure II-6.  Characterization of CTX-Clv 
 
II-6 a-d (Left) Overlays of the total current elicited by a 20 mV pulse from oocytes 
expressing Q1/E1 and Q1/E1T14C complexes.  Scale bars are 0.5 µA and 0.5 s.  (Right) 
Normalized CTX-sensitive current (I/Imax).  Oocytes were depolarized every 30 s and 
the data points were obtained at the end of a 5 s pulse.  Gray and red data points 
correspond to the raw traces on the left. 
 
a) One cycle of treatment.  Q1/E1T14C complexes were treated with 10 nM CTX-Clv, 
followed by washout and 1 mM TCEP treatment, demonstrating one complete 
modification cycle. 
   
b) Reversible inhibition of Q1/E1WT channels.  Irreversible inhibition of Q1/E1 
complexes requires an extracellular cysteine in E1 since wild type Q1/E1 complexes are 
only reversibly inhibited by 10 nM CTX-Clv. 
 
c) Irreversible inhibition of Q1/E1T14C by 10 nM CTX-Clv is completely prevented 
in the presence of excess CTX (unlabeled).  CTX-Clv did not modify the Q1/ E1T14C 
complex in the presence of 500 nM competitor (unlabeled CTX), as evidenced by 
complete washout demonstrating the non-specific bimolecular reaction between CTX-Clv 
and E1T14C does not measurably occur. 
 
d) A tethered CTX-Clv prevents modification of the unmodified E1 peptides in 
Q1/E1T14C complexes by CTX-Mal.  Q1/E1T14C complexes were irreversibly inhibited 
by CTX-Clv, inhibited complexes were then treated with CTX-Mal and the reagent was 
washed out.  Treatment with TCEP restored current showing a covalently tethered CTX-
Clv prevents further toxin-accelerated modifications of the other KCNE peptides in the 
channel complex. 
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Figure II-7.  Expression of exogenous KCNE peptides in Xenopus oocytes results in 
assembly with endogenous Q1 channels and measurable cell surface expression. 
 
Two-electrode voltage clamp recordings are in KD50 solution.  Currents were elicited by 
a family of command voltages from – 100 to 60 mV at 20-mV increments.  Dashed line 
indicates zero current.  Scale bars represent 1 µA and 0.5 s. 
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With this now battle-tested reagent, CTX-Clv was used to count the number of KCNE 
peptides in the Q1 K+ channel complex.  Q1/E1T14C complexes were repetitively 
subjected to the modification cycle:  CTX-Clv treatment, washout, and TCEP reductive 
cleavage (Figure II-9).  The first two rounds required TCEP treatment to release CTX-
Clv from the K+ channel complex.  The second round of CTX-Clv treatment proceeded 
as smoothly as the first, demonstrating that the molecular remnants left on the KCNE 
peptide after TCEP cleavage do not interfere with a subsequent round of binding and 
modification.  In the third round, CTX-Clv once again inhibited the K+ channel complex; 
however, inhibition was completely reversible with a simple washout, showing that it 
only takes two modification cycles to react with all of the KCNE peptides in a K+ channel 
complex. 
Although Figure II-6d demonstrated that a CTX-Clv bound and tethered to a K+ 
channel complex prevents subsequent KCNE modifications by CTX-Mal, it was not 
directly shown that one, and only one, KCNE peptide reacts per CTX-Clv treatment.  To 
do this, the difference in the probability mass function when n = 2, 4, or any even number 
of KCNE subunits (see Binomial Analysis of Modification) was used.  Q1/E1T14C 
complexes were pre-treated with a membrane-impermeant maleimide (MAL-ES) (Lu et 
al., 2007) to randomly and independently react with a fraction of the cysteines in the N- 
terminus of the E1 peptide.  Then the percentage of Q1/E1T14C complexes that were fully 
modified by this pre-treatment was determined by measuring the reversibility of CTX-
Clv after one round of treatment and washout (Figure II-10).  Based on the 19% 
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a) 
 
 
 
b) 
 
 
 
 
Figure II-8.  CTX-Mal reagent is resistant to TCEP cleavage  
 
(a) structure of CTX-Mal (detailed synthesis in chapter III), a non-cleavable version of 
CTX-Clv. (b) TCEP does not cleave CTX-Mal.  KCNQ1-KCNE1T14C channels are 
irreversibly inhibited by 10 nM CTX-Mal treatment, and remain inhibited upon treatment 
with 5 mM TCEP. Current was monitored at +20 mV every 15 s. 
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reversible inhibition that was observed, the binomial distribution predicts that a second 
round of treatment with CTX-Clv would result in 69% reversibility if only one KCNE is 
modified per CTX-Clv treatment; 88%, if two KCNE peptides react per treatment.  
Cleavage of the previously tethered CTX-Clv, followed by another bolus of CTX-Clv, 
and washout resulted in 65 ± 4% (s.e.m.) reversibility (n = 3).  We conclude that a 
tethered CTX-Clv protects unreacted E1 peptides from modification during the same 
round of treatment, that one and only one E1 peptide is modified per round of treatment, 
and therefore Q1 channels partner with 2 E1 β-subunits and this ratio remains fixed.  
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Figure II-9   KCNQ1 K+ channel complexes contain 2 KCNE1 peptides. 
 
Iterative counting of E1T14C subunits in a Q1 K+ channel complex.  (Above) Raw data 
showing the total current for each round.  Scale bar is 0.5 µA and 0.5 s.  (Below) 
Q1/E1T14C complexes were treated with two rounds (10 nM CTX-Clv, washout, 1 mM 
TCEP) of treatment before CTX-Clv binding became reversible.  Oocytes were 
depolarized every 30 s and the data points were obtained at the end of a 5 s pulse.  Gray 
and red data points correspond to the raw traces above.    
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Figure II-10    Only one KCNE peptide reacts per CTX-Clv treatment. 
 
(Above) CTX-sensitive current for each round.  Scale bar is 0.5 µA and 0.5 s.  (Below)  
Chemical modification of 19% of the cell surface Q1/ E1T14C complexes with 10 µM 
Mal-ES predicts that the reversibility of CTX-Clv in the second round will be 69% if one 
KCNE peptide reacts per round; 88% if two KCNE are modified per round (dotted lines, 
which correspond to two or four KCNE subunits in the K+ channel complex).  Washout 
of CTX-Clv after the second round of treatment results in 65 ± 4% (s.e.m.) reversibility 
(n = 3).  I/Imax is the CTX-sensitive current that was normalized before chemical 
treatment.  Gray and red data points correspond to the CTX-sensitive currents above. 
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Discussion 
 
A tethered blocker approach was used to count KCNE β-peptides in a functioning 
Q1/E1 complex.  It was reasoned that toxin binding is required for E1 modification and 
the non-specific bimolecular reaction between CTX-Clv and E1T14C does not measurably 
occur.  This was based on model reactions between positively charged maleimides and 
thiols, which suggested the modification of E1T14C by CTX-Clv is ~ 1000-fold faster than 
the unaided bimolecular reaction (Lu et al., 2007).  The observed accelerated 
modification rate indicated that toxin binding was required for modification and suggests 
that the non-specific bimolecular reaction between CTX-Clv and E1T14C does not 
measurably occur.  Figure II-6c directly shows binding is required before modification 
since CTX-Clv did not modify the Q1/ E1T14C complex in the presence of excess 
competitor (unlabeled CTX).   
In all experiments, only ~85% of the total current could be inhibited (reversibly or 
irreversibly); even in the presence of 250 nM wild-type CTX (figure II-6c), which based 
on the calculated dissociation constant for CTX-sensitive Q1/E1 complexes should afford 
99.9% inhibition (Chen et al., 2003).  We did not expect 100% block because Xenopus 
oocytes possess low levels of endogenous, CTX-insensitive Q1 channels that migrate to 
the cell surface with the injection of KCNE mRNAs (FigureII-7).  Moreover, the near 
quantitative reactions observed in each round indicate that Q1/E1 complexes at the cell 
surface are essentially devoid of endogenous Xenopus KCNE peptides (Gordon et al., 
2006) since their incorporation would result in incomplete modification cycles and 
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reversibility with CTX-Clv.  The kinetics of CTX-Clv unbinding and the percent 
recovery did not vary from round to round (Table II-1). 
The second competition experiment using CTX-Mal showed that a covalently 
tethered CTX-Clv acts as a highly concentrated competitive inhibitor and prevents further 
toxin-accelerated modifications of the other KCNE peptides in the channel complex.  The 
results showed channels treated first with CTX-Clv and second with CTX-Mal were 
irreversibly blocked as expected.  Upon TCEP treatment current fully returned indicating 
K+ channel complexes with a tethered CTX-Clv are protected from subsequent 
modifications.  Had CTX-Mal slipped past CTX-Clv and reacted with an E1 peptide, it 
would have been revealed as remaining block even after TCEP treatment.  This was not 
the case as all current returned (Figure II-6d).   
  The results from the counting experiment (figure II-9) that show complete 
irreversible block during the first two cycles of CTX-Clv treatment and the results from 
the competition experiment with CTX-Mal (figure II-6d) indicate that mixed 
stoichiometries do not exist.  If mixed stoichiometries were possible, partial return of 
current would be observed during the washout step (prior to cleavage) (figure II-9 ) and 
complete return of block would not have been observed due to non-cleavable CTX-Mal 
tethering (figure 6d), neither of these scenarios were observed.  Our results clearly show 
that the channels have an even number of E1 peptides, but do not rule out the possibility 
that we were modifying two E1 peptides per treatment.   
We directly showed that one, and only one, KCNE peptide reacts per CTX-Clv 
treatment by utilizing the difference in the probability mass function when n = 2, 4, or 
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any even number of KCNE subunits (figure II-10).  Oocytes expressing Q1/E1T14C were 
treated with Mal-ES to non-specifically label cell surface cysteines; we did not know 
which or how many cysteines were reacted with during our treatment.  One cycle of 
treatment with CTX-Clv reveals this however, and using the probability of mass function 
we predicted how much return of current (without cleaving) we would see during a 
second cycle of treatment, if there are two, three, four or more E1subunits.  Fortunately, 
the numerical difference between each scenario is within our experimental measure.  We 
performed the experiment and saw our results matched (within error) the predicted value 
observed if channels posses just two subunits.  In fact, this experiment shows there are 
just two E1 subunits per channel; we did not want to draw our conclusions on this data 
alone, however, since we were matching our data to a predetermined outcome.  Our 
supporting counting experiment (figure II-9) allows us to conclude that there are two 
KCNE peptides in a Q1 K+ channel complex, resulting in a complex that is not four-fold 
symmetric. 
The 4:2 (α:β) stoichiometry of the Q1/E1 complex has several broad implications 
on KCNE modulation of voltage-gated K+ channels.   If modulation is due to a direct 
KCNE–K+ channel protein-protein interaction, then KCNE peptides either interact with 
only two of the α-subunits in a K+ channel complex or they bifurcate adjacent α-subunits, 
making two unique sets of protein contacts with all four ion conducting subunits (Chen et 
al., 2003; Liu et al., 2007; Kang et al., 2008).  Alternatively, KCNE modulation of K+ 
channels could be allosteric in nature; the two subunits cooperate to influence protein 
conformation, thereby influencing modulation.  Likewise, mutant KCNE peptides that 
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produce diseased K+ channel complexes (Splawski et al., 1997; Sesti and Goldstein, 
1998; Splawski et al., 2000; Ma et al., 2003) will impart their deleterious effects on ion 
conduction and channel gating due to their bifurcation of subunits or allosteric regulation.  
Interpreting the effects of KCNE peptides on K+ channel function is made even 
more complex with the discovery that a single Q1 channel can assemble with two 
different KCNE peptides to form a functional heteromeric complex (Morin and Kobertz, 
2007).  However, since each K+ channel complex contains only two KCNE peptides, this 
allows for a simplified means of controlling K+ conduction by greatly reducing the 
number of potential heteromeric complexes that can form. 
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Table II-1.  Recovery parameters after CTX-Clv application1 
Construct Treatment τrecovery (s) % recovery n 
Q1/E1 CTX-Clv 98  ± 1 95  ± 2? 5 
Q1/E1T14C CTX-Clv, TCEP 97  ± 1 96  ± 2 4 
Q1/E1T14C CTX-Clv + excess CTX     155  ± 4  96  ± 1 3 
Q1/E1T14C 
CTX-Clv, CTX-Mal, 
TCEP 94  ± 3 94  ± 1 3 
Q1/E1T14C Round 1, TCEP 96  ±2 96  ± 2 3 
Q1/E1T14C Round 2, TCEP 98  ± 3 98  ± 4 3 
Q1/E1T14C Round 3 97  ± 1 94  ± 3 3 
 
1Data are from individual experiments obtained from 3–5 oocytes.  Treatment 
describes the sequential application of chemical reagents to the indicated construct.  
Round 1, Round 2, Round 3 indicates the 1st, 2nd, and 3rd rounds of subunit counting 
(Figure II-10), respectively. Time constants of recovery were fit to a single 
exponential as described in Material and Methods.  Percent recovery is a comparison 
between the amount of current remaining after CTX-Clv release to the amount of 
current before CTX-Clv application.   Values are mean ± SEM. 
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CHAPTER III: A Derivatized Scorpion Toxin Reveals the Functional 
Output of Heteromeric KCNQ1–KCNE K+ Channel Complexes 
 
 
Abstract 
 
KCNE transmembrane peptides allow Q1 channels to produce the diversity of 
potassium currents needed for proper function in a variety of cells.  Although all five 
KCNE transcripts have been found in cardiac and other tissues, it is unclear whether two 
different KCNE peptides can assemble with the same K+ channel to form a functional 
complex.  To test this hypothesis, I utilized a derivatized scorpion toxin that irreversibly 
inhibits Q1 channel complexes that contain a specific KCNE peptide.  Using this KCNE 
sensor, it was shown that heteromeric complexes form, and the functional output from 
these complexes reveals a hierarchy in KCNE modulation of Q1 channels: E3 > E1 >> 
E4.  Furthermore, the results demonstrate that Q1/E1/E4 complexes also generate a 
slowly activating current that has been previously attributed to homomeric Q1/E1 
complexes, providing a potential functional role for KCNE4 peptides in the heart. 
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Introduction 
 
To meet the potassium conduction requirements for a wide variety of tissues, Q1 
K+ channels co-assemble with different KCNE β-subunits to afford membrane-embedded 
complexes with distinctive gating properties.  In the heart, the Q1/E1 K+ channel 
complex has long been thought to generate the slowly activating cardiac IKs current 
(Barhanin et al., 1996; Sanguinetti et al., 1996).  In contrast, E2 and E3 subunits have 
been shown to assemble with Q1 channel subunits in epithelial cells where they maintain 
salt and water homeostasis (Schroeder et al., 2000; Roepke et al., 2006).  The biological 
roles of Q1/E4 and Q1/E5 complexes have yet to be defined.   
Since current kinetics and amplitude of Q1 channels is controlled by KCNE 
peptides, their tissue distribution has been assumed to underlie Q1–KCNE complex 
modulation in vivo.  Recently, all five KCNE transcripts have been detected in cardiac 
(Bendahhou et al., 2005; Lundquist et al., 2005) and other tissues (Lundquist et al., 2006), 
raising the possibility that two different KCNE peptides can assemble with the same Q1 
channel to form a heteromeric complex.   Determining the functional output of 
heteromeric Q1–KCNE complexes has been hampered by the fact that macroscopic 
electrical recordings measure the total current from a cell, making it difficult to 
deconvolute the contribution of heteromeric complexes (e.g., Q1/E1/E4) from two 
populations of homomeric complexes (e.g., Q1/E1 and Q1/E4) functioning at the cell 
surface.  Co-immunoprecipitation of one KCNE peptide by another KCNE peptide has 
indirectly hinted at heteromeric complex formation (Wu et al., 2006; Manderfield and 
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George, 2008).  However, these qualitative biochemical experiments are unsatisfying 
given that it is unclear whether these precipitated complexes are functional.  To 
determine whether heteromeric complexes function at the cell surface, a tethered blocker 
approach in combination with electrophysiological recordings was used.  
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Materials and Methods 
 
Mutagenesis and in Vitro Transcription 
The CTX sensitive Q1 construct (Chen et al., 2003), E1, E3, and E4 were subcloned into 
a vector containing the 5’ and 3’ untranslated regions from the Xenopus β-globin gene 
for optimal expression in Xenopus oocytes.  Single point mutations in KCNE peptides 
were introduced using QuikChange site-directed mutagenesis (Stratagene).  Mutated 
sequences were confirmed by DNA sequencing of the entire gene.  E1 and E3 constructs 
possessed the hemagglutinin (HA) tag, YPYDVPDYA, in the N-terminus between 
residues 22 and 23 and 11 and 12, respectively, which has been shown to increase CTX 
toxin affinity (Chen et al., 2003). The complementary DNA plasmids were linearized 
with Mlu I, and complementary RNA was synthesized by run-off transcription using SP6 
(E1) or T7 (E3 and E4) RNA polymerase (Promega). 
 
 
Electrophysiology 
Standard techniques were used for preparation of and recording from Xenopus 
oocytes by two-electrode voltage clamp 2–4 d (5–6 d for E4) after cRNA injection 
(methods chapter II Oocyte preparation). Oocytes expressing KCNE extracellular 
cysteine residues were stored in ND96 bathing solution (96 mM NaCl, 2 mM KCl, 1.8 
mM CaCl2, 5 mM HEPES, pH 7.4), 50 µg mL-1 gentamicin containing 2 mM L-
glutathione (Sigma) and incubated in ND96 recording (96 mM NaCl, 2 mM KCl, 0.3 mM 
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CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4, containing 1 mM TCEP (CalBioChem)) for 
10 min prior to recording.  cRNA injection ratios were as follows: Q1/E1, Q1/E1T14C, 
Q1/E3, Q1/E3C31S, and Q1/E4L2C, 3:1; Q1/E1T14C/E3C31S, Q1/E1/E3, and Q1/E4L2C/E3C31S, 
4:1:0.2; Q1/E1/E4L2C, 4:1:1.   
To generate activation curves (Activation Curve Analysis), current–voltage 
relationships were measured in ND96 or KD50 (50 mM KCl, 48 mM NaCl, 0.3 mM, 
CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4) by holding at -80 mV and pulsing for 2 or 
4 s to potentials between -100 and +60 mV in 10-mV increments for 4 s, after which 
oocytes were returned to – 80 mV.  The interpulse interval was 15 s.    
For CTX experiments, bath solutions also contained 50 µg mL-1 bovine serum 
albumin. Solution exchanges were performed by gravity-fed perfusion system with a 
chamber clearing time of ~10 s. Families of currents before and after CTX-Mal block 
were recorded in the appropriate bath solution by holding at -80 mV and pulsing from -
100 to +60 mV in 20 mV increments.  Currents from heteromeric Q1–KCNE complexes 
(Q1/E1/E4, Q1/E3/E4, Q1E3/E1) were revealed by subtracting block after CTX-Mal 
washout families from pre-block family traces (Clampfit 9.0 Axon Instruments). 
 
 
Activation Curve Analysis 
The amplitude of the tail currents were measured 3 ms after return to – 80 mV and 
plotted versus the depolarized potential.  The resultant activation curves were initially fit 
to a Boltzmann function, y = A2 + (A1-A2)/(1+e(V-V½ )*(-zF/RT)), where V½ is the midpoint 
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of activation and z is the maximum slope.  The upper and lower asymptotes, A1 and A2, 
respectively, were left to vary, allowing data to be fit in cases where channels did not 
fully close or were not fully activated in the voltage ranges that can be used with oocytes 
(-100 to +60 mV).  After the initial fit, the tail current amplitudes were normalized such 
that the upper asymptote (A1) was equal to 1.  These data were refit to the Boltzmann 
function, and the lower asymptote (A2) of the second fit was used to compare basal 
activation of the wild type Q1-E3 complexes.  
 
 
CTX Derivatization.  
Recombinant CTX R19C was purified and the protected CTX-MTSET adduct was 
prepared according to Shimony et al. (Shimony et al., 1994). CTX-Mal was synthesized 
as follows: 16 nmol of CTX-MTSET in 2 mL of Buffer C (10 mM NaCl, 10 mM KPi, pH 
7.4) was reduced with 1 mM DTT for 30 min and bound to a SP Sephedex (Sigma) cation 
exchange column. DTT was washed from the column using 150 mL of Buffer C, and the 
resin bound CTX was labeled with 3 mL of 5 mM BM[PEO]3 (Pierce) in Buffer C. After 
10 min, the column was washed with Buffer C to remove excess label, and CTX-Mal was 
eluted with 1 M NaCl in 10 mM KPi, pH 7.4.  CTX-Mal was desalted and HPLC purified 
using a C18 column (4.6 mm  250 mm) eluting with solvent A (0.1% TFA)/solvent B 
(acetonitrile) gradient 10% to 40% B over 30 min. The concentration of purified CTX-
Mal was determined by UV spectrometry (OD280 of 1.0 100 µM CTX (Shimony et al., 
1994) and labeling efficiency of CTX-R19C was determined to be 35% ± 5% (n = 10). 
 59 
The purified product was confirmed by electrospray ionization mass spectrometry (Figure 
III-1) and was aliquoted, lyophilized, and stored at -20 °C. Individual aliquots were 
resuspended in recording solutions immediately prior to use. 
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Figure III-1   CTX-Mal electrospray mass spectrum (positive mode). 
 
Expected MW for CTX-Mal:  4593.0 (methionine oxidized); +3, 1532.0; +4, 1149.3; +5, 
919.6; +6, 766.5. 
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Results 
 
KCNE peptides have a striking effect on the opening and closing of Q1 channels, 
and these gating differences have been traditionally used to identify the composition of 
homomeric Q1–KCNE complexes (Figure III-2).  Q1/E1 complexes are strongly voltage-
dependent and upon depolarization give rise to a slowly activating K+ current (Barhanin 
et al., 1996; Sanguinetti et al., 1996) whereas Q1/E3 complexes are open at both negative 
and positive voltages and have nearly instantaneous gating kinetics (Figure III-2) 
(Schroeder et al., 2000).  In contrast, when Q1 assembles with E4, the complexes are 
essentially non-conducting at the plasma membrane (Figure III-2) (Grunnet et al., 2002). 
Coexpression of Q1 and E1 with E3 or E4 results in an amalgam of currents (Figure III-
2), and visual inspection or activation curve analysis (Figure III-2) does not reveal 
whether there are heteromeric Q1–KCNE complexes functioning at the plasma 
membrane.  
To detect KCNE peptides in functioning Q1 channel complexes, a synthetically 
modified charybdotoxin (CTX) was generated to specifically react with cysteine residues 
within the N-termini of KCNE peptides (Figure III-3a).  As discussed in Chapter 2, an 
arginine on the backside of the toxin can be mutated to cysteine (R19C) for derivatization 
without affecting its affinity for K+ channels (Shimony et al., 1994; Posson et al., 2005).  
To convert CTX into a cysteine reactive inhibitor (CTX-Mal), R19C mutated 
charybdotoxin was purified as a fusion protein from E. coli and subsequently purified as 
the mixed disulfide CTX-MTSET adduct.  CTX-MTSET was reduced with DTT, bound 
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to a cation exchange column, labeled with 100-fold excess bismaleimide (BM-PEO3) 
(Pierce) (figure III-3b) and HPLC purified after elution with high salt (see Methods 
section for details).  
As mentioned in Chapter II, CTX does not inhibit native Q1/E1 complexes; 
therefore, we utilized a variant of Q1 (Q1*) that is blocked by nanomolar concentrations 
of toxin (Chen et al., 2003). CTX-sensitive Q1/E1 complexes do not possess any 
extracellular cysteines and thus CTX-Mal should reversibly bind to these complexes.  
When cells expressing CTX-sensitive Q1/E1 complexes were treated with 10 nM CTX-
Mal, the current was blocked, and then upon washout, it fully recovered to pretreated 
levels, demonstrating that inhibition was reversible (Figure III-4a).  Q1/E3 complexes 
were also reversibly blocked by CTX-Mal when the lone cysteine in E3 (C31S) was 
removed by mutagenesis (Figure III-4b). These control experiments showed that 
chemical derivatization of CTX did not disrupt binding to the Q1 channel pore. 
Next the N-terminus of E1 was cysteine-scanned to find residues that were 
covalently modifiable by CTX-Mal.  The N-termini of KCNE peptides are ideal for 
cysteine mutagenesis because these regions in E1 and E3 are not required for assembly 
with or modulation of Q1 channels (Takumi et al., 1991; Gage and Kobertz, 2004).  
Mutation of three E1 residues (Thr14, Gln22, and Ser34) to cysteine resulted in Q1/E1 
complexes with wild-type gating kinetics that were irreversibly blocked by CTX-Mal.  
Q1/E1T14C complexes were the most reactive, showing no relief of inhibition upon 
washout of CTX-Mal (Figure III-4c).  Covalent tethering of CTX-Mal to Q1/E1T14C 
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Figure III-2   Co-expression of KCNQ1 channels with two different KCNE peptides 
gives rise to an amalgam of voltage-dependent and -independent currents. 
 
(Top)  Two-electrode voltage clamp recordings for homo- and heteromeric Q1-
KCNE complexes.  Inspecting current traces alone does not reveal heteromeric complex 
formation as opposed to two homomeric populations giving visually hybrid macroscopic 
current. Currents were elicited by a family of command voltages from –100 to 60 mV at 
20-mV increments and recorded in KD50 solution.  Dashed line indicates zero current.  
Scale bars represent 1 µA and 0.5 s.  (bottom)  Voltage-activation curves of homo- and 
heteromeric Q1-KCNE complexes.  The data were fit to a Boltzmann and normalized 
for channels that are open at negative potentials (Gage and Kobertz, 2004).  Data were 
averaged from 3–5 oocytes each and error bars are ± SEM.   Activation curve analysis 
does not reveal whether there are heteromeric Q1–KCNE complexes functioning at the 
plasma membrane. 
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Figure III-3   Cartoon depiction of the toxin tethering reaction between CTX-Mal 
and a cysteine residue in E1 and CTX-Mal reagent synthesis. 
 
a)  To detect KCNE peptides, a synthetically modified charybdotoxin (CTX) was 
generated to specifically react with cysteine residues within the N-termini of KCNE 
peptides.  Shown is the strategy to detect E1 peptides in Q1/E1/E3 heteromeric 
complexes.  b)  MTSET protected CTX was reduced and reacted with 100 fold excess 
BM[PEO]3, the final product was HPLC purified and confirmed by ESI-MS. 
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required binding to the channel pore given that the reaction was completely prevented by 
competitive inhibition with 250 nM CTX (Figure III-4d).  As was observed in Chapter 2, 
only ~ 85% of the total current could be inhibited (reversibly or irreversibly); even in the 
presence of 250 nM wild-type CTX, (Figure III-4d), which is presumably due to the low 
levels of endogenous, CTX-insensitive Q1 channels that migrate to the cell surface with 
the injection of KCNE mRNAs (figure II-7).  
Armed with a reagent to detect KCNE peptides in K+ channel complexes, we 
determined whether Q1/E1/E3 complexes assemble and are functional. We first placed 
the target cysteine in E1 (and removed the native cysteine in E3, C31S).  Coexpression of 
Q1/E1T14C/E3C31S resulted in both outward and inward currents in response to a family of 
depolarizations in a 50 mM external K+ solution that allows for the visualization of the 
inward currents (shaded pink) (Figure III-5).  Treatment of these cells with CTX-Mal 
covalently modifies and irreversibly blocks Q1 channel complexes that have assembled 
with E1T14C peptides. Upon washout, ~80% of the CTX-sensitive current generated by     
a -100 mV test potential was irreversibly inhibited (Figure III-5).  The 80% reduction in 
current must be a result of blocking Q1/E1T14C/E3C31S complexes since Q1/E1T14C 
complexes, even though irreversibly blocked in this assay, are closed and do not pass 
inward current at -100 mV (Figure I-2).  The remaining 20% of inward current comes 
from Q1/E3C31S, which lacks the cysteine and therefore cannot be irreversibly blocked 
(Figure III-5 after).  Examination of the current–voltage traces after CTX-Mal washout 
(Figure III-5 after) shows an E1 component, which we postulate is due to endogenous 
CTX-insensitive Q1 channels partnering with E1T14C that cannot be blocked by CTX.  To 
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a)                                   b) 
 
     
 c)                                          d) 
 
 
Figure III-4   Characterization of CTX-Mal on Q1/KCNE channels.   
 
a and b)  Reversible inhibition of Q1-KCNE complexes that lack extracellular 
cysteines.  a) Q1/E1 and b) Q1/E3C31S complexes are not permanently inhibited with 10 
nM CTX-Mal in ND96 solution.  Current was monitored at 20 mV every 15 s.  
c and d)  Application of CTX-Mal to Q1/E1T14C complexes.  c)  Single cysteine 
containing Q1/E1T14C complexes were irreversibly inhibited as demonstrated by no 
current return after CTX-Mal washout.   d) Inhibition was completely prevented in the 
presence of excess (250 nM) CTX showing CTX-Mal must bind to the channel to allow 
tethering between the reactive maleimide and thiol containing cysteine to occur. 
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visualize the currents that are irreversibly blocked by CTX-Mal, we mathematically 
subtracted the remaining current after block from the before block currents (Figure III-5 
subtraction).  This allowed visualization of the macroscopic current coming from a 
mixture of Q1/E1T14C and Q1/E1T14C/E3C31S complexes at the cell surface. 
To determine whether Q1/E1/E3 complexes possess any time-dependent 
activation at positive potentials, we utilized the native cysteine in E3 and looked at 
irreversible block of outward currents in wild-type Q1/E1/E3 complexes.  In this assay 
Q1/E1/E3 and Q1/E3 channels were irreversibly blocked due to the native cysteine in E3, 
while Q1/E1 channels (lacking the cysteine) were reversibly inhibited.  In this 
configuration, subtraction of the after traces from before reveals the macroscopic current 
of blocked Q1/E1/E3 and Q1/E3 complexes.  After CTX-Mal treatment and subsequent 
washout of cells expressing Q1/E1/E3, we saw a reduction of both inward and outward 
currents as before (Figure III-6).  Mathematical subtraction revealed that heteromeric 
Q1/E1/E3 complexes slowly activate at positive voltages and slowly deactivate upon 
repolarization (Figure III-6 subtraction). 
Next it was determined whether Q1/E1/E4 complexes were functional. E4 is the 
most abundant KCNE transcript in heart (Bendahhou et al., 2005; Lundquist et al., 2006), 
yet when the peptide assembles with Q1, it produces a non-conducting channel complex 
(Figure III-2) (Grunnet et al., 2002).  Therefore, to detect functional Q1/E1/E4 complexes, 
the cysteine residue was placed in E4. When E4L2C was coexpressed with Q1/E1, the 
resultant CTX-sensitive currents in ND96 solution were irreversibly blocked (52% ± 3%) 
by CTX-Mal upon washout (Figure III-7).  Irreversible blockade of any current indicates 
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Figure III-5   Detection of heteromeric Q1/E1/E3 complexes with CTX-Mal. 
 
Q1/E1T14C/E3C31S current traces shown are pre-treatment (Before) and after 
washout (After) of 10 nM CTX-Mal.  Currents were measured in KD50 solution and 
were from command voltages (– 100, – 80, – 60, 0, 20, and 40 mV).    Outward currents 
are shaded blue; inward are shaded red.  Dashed line indicates zero current.  Scale bars 
represent 1 µA and 0.5 s.   
 
Reaction profiles (Reaction) with 10 nM CTX-Mal were monitored at – 100 mV every 
15 s in KD50 solution.  For Q1/E1T14C/E3C31S, 78 ± 2% of the CTX-sensitive current was 
irreversibly inhibited after washout.    
 
Mathematical subtraction reveals heteromeric Q1/E1T14C/E3.   Complexes show the 
inward current afforded by heteromeric Q1/E1/E3 complexes.  Subtraction traces are a 
mathematical difference of the After and Before traces.  Outward currents are shaded 
blue; inward are shaded red.  Dashed line indicates zero current.  Scale bars represent 1 
µA and 0.5 s. 
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Figure III-6    Detection of heteromeric Q1/E1/E3 complexes with CTX-Mal 
assaying Q1/E1/E3 (using native cysteine (C31) in E3). 
 
Current traces shown are pre-treatment (Before) and after washout (After) of 10 nM 
CTX-Mal.  Currents were measured in KD50 solution and were from command voltages 
(– 100, – 80, – 60, 0, 20, and 40 mV).  Outward currents are shaded blue; inward are 
shaded red.  Dashed line indicates zero current.  Scale bars represent 1 µA and 0.5 s.   
 
Reaction profiles (Reaction) with 10 nM CTX-Mal were monitored at – 100 mV every 
15 s in KD50 solution.  74 ± 4% of the CTX-sensitive current was irreversibly inhibited 
after washout. Data were averaged from 3–5 oocytes ± SEM.   
 
Mathematical subtraction reveals that heteromeric Q1/E1/E3.  Complexes slowly 
activate at positive voltages and slowly deactivate upon repolarization.  Subtraction 
traces are a mathematical difference of the After and Before traces.  Outward currents are 
shaded blue; inward are shaded red.  Dashed line indicates zero current.  Scale bars 
represent 1 µA and 0.5 s. 
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Q1/E1/E4 complex assembly given that homomeric Q1/E4L2C complexes are like wild-
type Q1/E4 and non-conducting. 
The amount of irreversible inhibition measured was predictably dependent on the 
ratio of E1/E4L2C expressed. Injection ratios that favored the formation of Q1/E1 
homomers resulted in a reduction of irreversible block, whereas injection of more E4L2C 
mRNA resulted in an increase of irreversible block (Figure III-7 bottom).  Subtraction of 
the after traces from the before traces revealed the gating kinetics of Q1/E1/E4 
complexes (Figure III-7 top).  Since the gating kinetics of Q1/E1/E4 complexes looked 
very similar to Q1/E1 currents, we were curious if E4 had any effect on channel 
activation.  Recording Q1/E1/E4L2C families in KD50, treating with CTX-Mal and 
subtracting after currents from before allowed for the generation of activation curves for 
the heteromeric Q1/E1/E4 complex.  Current-voltage analysis of tail current recordings in 
high K+ shows virtually no change in the voltage dependence of activation (Figure III-8). 
E4 also forms functional heteromeric Q1 complexes with E3. Q1/E3C31S/E4L2C 
complexes were irreversibly inhibited by CTX-Mal in ND96 solution (Figure III-9), and 
again, subtraction of the after traces from the before traces revealed the gating kinetics of 
Q1/E3/E4 complexes (Figure III-9 subtraction).  Although E4 is present in both 
heteromeric complexes studied, the peptide has little effect on the gating kinetics. Thus 
for Q1 channels, E3 and E1 dictate gating in heteromeric complexes with E4 peptides. 
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Figure III-7   E4 peptides form heteromeric complexes with Q1 and E1. 
 
(Top)  Q1/E1/E4L2C  current traces shown are pre-treatment (Before) and after washout 
(After) of 10 nM CTX-Mal.  Currents were measured in ND96 and elicited by a family of 
command voltages from – 100 to 40 mV with 20-mV steps.  Dashed line indicates zero 
current.  Scale bars represent 1 µA and 0.5 s.  Reaction profiles (Reaction) with 10 nM 
CTX-Mal were monitored at 20 mV every 15 s in ND96 solution.  For Q1/E1/E4L2C, 52 ± 
3% of the CTX-sensitive current was irreversibly inhibited after washout.  Data were 
averaged from 2–5 oocytes ± SEM.  Mathematical subtraction reveals gating kinetics of 
Q1/E1/E4 heteromeric complexes.  Subtraction traces are a mathematical difference of 
the After and Before traces.  Dashed line indicates zero current.  Scale bars represent 1 
µA and 0.5 s. 
   
(Bottom)    Irreversible block of Q1/E1/E4L2C complexes is dependent on the 
amount of E4L2C.  RNA injection rations were varied (E1:E4L2C):  5:1, squares; 1:1 
triangles; 1:5 open circles, which yielded 19 ± 3%, 52 ± 3%, and 86 ± 4 irreversible block 
of the CTX-sensitive current after washout.  Data were averages from 2—5 oocytes. 
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Figure III-8.  Current voltage analysis of Q1/E1 currents v. Q1/E1/E4 complexes. 
 
(Left and Middle)  Currents were measured in KD50 and elicited by a family of 
command voltages from – 100 to 40 mV with 20-mV steps.  Scale bars represent 1 µA 
and 0.5 s.  Voltage-activation curves of  Q1/E1  and Q1/E1/E4 complexes.  The data 
were fit to a Boltzmann, data were averaged from 3–5 oocytes each and error bars are ± 
SEM.    
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Figure III-9.    KCNE4 peptides form heteromeric complexes with KCNQ1 and 
KCNE3.    
 
Q1/E3C31S/E4L2C current traces shown are pre-treatment (Before) and after washout 
(After) of 10 nM CTX-Mal.  Currents were measured in ND96 and elicited by a family 
of command voltages from – 100 to 40 mV with 20-mV steps.  Dashed line indicates zero 
current.  Scale bars represent 1 µA and 0.5 s.  Reaction profiles (Reaction) with 10 nM 
CTX-Mal were monitored at 20 mV every 15 s in ND96 solution.  For Q1/E3/E4L2C, 80 ± 
1% of the CTX-sensitive current was irreversibly inhibited after washout.  Data were 
averaged from 2 oocytes ± SEM.   Mathematical subtraction reveals gating kinetics 
and current voltage relationship of Q1/E3/E4 heteromeric complexes. Subtraction 
traces are a mathematical difference of the After and Before traces.  Dashed line indicates 
zero current.  Scale bars represent 1 µA and 0.5 s.   
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Discussion 
 
CTX-Mal was used to detect and visualize currents coming from heteromeric 
Q1/KCNE complexes.  Using this reagent we were able to conclude Q1/E1/E3, Q1/E1/E4, 
and Q1/E3/E4 heteromers form and function, and by mathematical subtraction of current 
after block from currents before block we were able to visualize currents coming from 
these mixed complexes.   
When the target cysteine was placed in E1 to examine Q1/E1/E3 complexes, the 
subtracted traces were a mixture of currents from Q1/E1 homomers and Q1/E1/E3 
heteromers.  However, since homomeric Q1/E1 complexes are closed and non-
conducting with test potentials less than – 30 mV (Figure III-2), the inward currents in 
the subtracted traces in Figure III-6 are entirely from Q1/E1T14C/E3C31S complexes.  
Unlike the inward currents, the outward currents (shaded blue) in the subtracted traces are 
contaminated with slowly activating homomeric Q1/E1T14C currents. 
 To visualize outward currents in Q1/E1/E3 and determine whether the complexes 
possess any time-dependent activation at positive potentials, we utilized the native 
cysteine in E3 and looked at irreversible block of outward currents in wild type Q1/E1/E3 
complexes.  The blocked outward currents in this configuration will still be a mixture of 
homo- and heteromeric complexes; however, the homomeric complexes are Q1/E3, 
which are devoid of slow gating (Figure III-2).  Thus, any slow gating observed would be 
due to heteromeric Q1/E1/E3 complexes.  Mathematical subtraction reveals that 
heteromeric Q1/E1/E3 complexes slowly activate at positive voltages and slowly 
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deactivate upon repolarization (Figure III-5 and III-6, Subtraction).  In total, these results 
show that the Q1/E1/E3 complex generates current with the combined properties of 
homomeric Q1/E1 and Q1/E3 complexes:  it is a heteromeric complex that closes slowly 
(E1-like), is partially open at negative potentials (E3-like), and slowly opens with 
positive depolarizations (E1-like). 
To ascertain whether Q1/E1/E4 complexes were functional we placed the target 
cysteine in E4.  Since Q1/E4 complexes are non-conducting any irreversible block we 
observe must be due to heteromeric Q1/E1/E4 complexes.  When E4L2C was co-expressed 
with Q1/E1, the resultant CTX-sensitive currents in ND96 solution were irreversibly 
blocked (52 ± 3%) by CTX-Mal upon washout (Figure III-7).  Furthermore, injection 
ratios that favored the formation of Q1/E1 homomers resulted in a reduction of 
irreversible block whereas injection of more E4L2C mRNA resulted in an increase of 
irreversible block (Figure III-7 bottom).  The difference between the after and the before 
traces revealed the gating kinetics of Q1/E1/E4 complexes (Figure III-7, Subtraction), 
which resemble the cardiac IKs current that has been attributed to Q1/E1 complexes.   
E4 also forms functional heteromeric Q1-complexes with E3.  Figure III-9 shows 
that Q1/E3C31S/E4L2C complexes were irreversibly blocked by CTX-Mal in ND96 
solution.  Although E4 is present in both heteromeric complexes studied, the peptide has 
little effect on the gating kinetics.  Thus for Q1 channels, E3 and E1 dictate gating in 
heteromeric complexes with E4 peptides.   
The results using CTX-Mal demonstrate that a tetrameric Q1 channel can 
simultaneously assemble with two different KCNE peptides.  In addition, we determined 
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that, when channels do pass current, certain KCNE peptides govern Q1 modulation in 
heteromeric complexes: E3>E1>>E4, where the dominant peptide has substantial control 
over the opening and closing of the channel. Although it was shown that heteromeric Q1–
KCNE complexes form, we cannot determine the assembly preference for KCNE 
peptides with Q1 subunits because an endpoint (current expression) was examined and 
not the biogenesis and stability of the protein subunits.  Assembly preference could be 
determined by assaying protein expression of each subunit.  The results also indicate that 
the N-termini of KCNE peptides are near the Q1 channel outer vestibule since the linker 
connecting CTX to the maleimide is too short to reach beyond the S3–S4 loop of the 
voltage sensor (Blaustein et al., 2000).  On the basis of a NMR structure of CTX bound to 
a bacterial K+ channel (Yu et al., 2005), the position the KCNE N-terminus is within 20 
Å of the ion conduction pathway. 
This hierarchy of KCNE modulation of Q1 channels has several implications for 
KCNE physiology.  In the heart, it has been assumed that homomeric Q1/E1 complexes 
produce the unmistakably slowly activating/deactivating IKs current involved in 
repolarization (Barhanin et al., 1996; Sanguinetti et al., 1996). E4 may also generate the 
cardiac IKs current because Q1/E1/E4 and Q1/E1 complexes have similar gating kinetics. 
Likewise, in most epithelial cells where the resting membrane potential is negative, the 
assembly of E1, E4, or E5 with Q1 has been questioned given that these complexes 
would be essentially closed. However, E1 and E4 peptides can act as structural surrogates 
in Q1/E3 heteromeric complexes to produce channels that are open at negative potentials 
and thus may partake in salt and water homeostasis (Schroeder et. al., 2000). In either 
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case, these heteromeric complexes can substitute for homomeric complexes; however, 
they require the presence of the dominant KCNE peptide, consistent with KCNE 
knockout mice studies (Vetter et al., 1996; Roepke et al., 2006).  
In contrast, over expression of constitutively conducting Q1/E1/E3 complexes 
could be detrimental in maintaining the cardiac action and resting potentials, suggesting 
that cells regulate Q1–KCNE assembly. Simple binary transcriptional regulation of 
functionally opposed KCNE peptides could be used to control the potassium efflux of a 
cell.  Alternatively, KCNE assembly with Q1 channel subunits may be regulated at the 
protein folding level. If Q1–KCNE assembly is chaperone mediated, these proteins must 
reside in either the ER or cis-Golgi since KCNE peptides assemble with Q1 channels 
early in the secretory pathway (Chandrasekhar et al., 2006).   
The discovery that heteromeric Q1–KCNE complexes are functionally expressed 
at the cell surface implies that other voltage-gated K+ channels will be amenable to co-
assembly with two (or more) different KCNE peptides.  Given the cadre of scorpion and 
spider toxins available to specifically inhibit a wide range of ion channels, our approach 
can be readily applied to study other membrane-embedded β-subunits in functioning ion 
channel complexes. 
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CHAPTER IV:  Toxin-directed labeling of K+ channel α- and β-
subunits in native cells 
 
Abstract 
 
A major limitation of the tethered blocker technology we have utilized in our 
studies in chapters II and III is that it requires an extracellular cysteine in the protein 
under study to provide a reactive handle and therefore is not compatible with most native 
proteins in vivo.  This limitation may be overcome by allowing native proteins to 
incorporate a non-native thiol into their overall structure through cellular post-
translational modifications.  This would provide the necessary chemical handle to allow 
toxin-directed chemical labeling of endogenous ion channels in native cell types and 
tissues.   
Chapter IV shows that Xenopus oocytes incubated in media containing the non-
natural sugar aceylated-thiol MaNAc (a sialic acid precursor) will take-up, de-acetylate 
and incorporate this thiolate-sugar into its extracellularly displayed N-linked glycans.  
KCNE β-subunits and Shaker channel α-subunits decorated with these thiol-glycans can 
be irreversibly blocked using CTX-Lclv-biotin, a derivatized charybdotoxin that upon 
linker cleavage labels channels with biotin.  Here, covalent tethering is through the 
exogenous thiol in the sugar, as opposed to a mutated cysteine residue as in Chapters II 
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and III.  This technique of tethered block through thiol-modified sugars provides a means 
for probing endogenous channels in native tissues. 
 
Introduction 
 
Expression systems are excellent tools for the structure-function characterization 
of voltage-gated ion channels and have proved instrumental in countless biophysical 
studies.  However, it is imperative that channels also be studied in their native cells under 
endogenous expression levels to fully understand their physiological roles.  This 
challenging task would be aided by the ability to selectively label a specific ion channel 
of interest in its native environment with experimentally useful probes, such as biotin and 
fluorophores.  Labeled endogenous channels would be valuable in identifying native 
partners, investigating trafficking pathways and cellular architecture, along with 
recycling and degradation rates, and localization studies.  Major hurdles to labeling a 
particular population of channels on the cell surface include: 1) the channel under study 
lacks a useful handle that would permit chemical modification, and/or 2) the labeling 
reagent is not specific for the channel under study.  For example, many available biotin 
and fluorescent labeling reagents non-specifically label all proteins on the cell surface 
that express a particular reactive group, commonly thiols or primary amines on 
extracellularly exposed amino acid side chains.   
The experiments discussed in previous sections of this thesis utilized channels 
that had mutant cysteines introduced into their extracellular loops.  We would like to 
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probe these channels in their native tissues without the need to transfect in the modified 
channel or subunit under study.  Based on previous work (Yarema et al., 1998; Dube and 
Bertozzi, 2003), it was reasoned that cells grown on unnatural sialic acid precursors that 
contain a thiol group (Figure IV-1a) would take-up and incorporate the modified sugar 
into N-linked glycans on glycoproteins trafficking through the Golgi to the plasma 
membrane.  This metabolic labeling approach would provide the necessary chemical 
handle to label native Shaker channels and KCNE β-subunits with channel specific toxin 
derivatives.   
To demonstrate the feasibility of this idea, CTX-Lclv-Biotin was developed.  This 
reagent is similar to those already discussed, which block and tether to channels through 
a covalent maleimide-thiol linkage; however, upon linker cleavage, current is restored 
and α- or β-subunits are permanently labeled with biotin (Figure IV-Ib).  The idea of 
using biotin as a label was two-fold; first, it would allow us to perform Western blot 
analysis for our labeled protein when showing proof of principle experiments, as there are 
many commercially available antibodies specific to biotin and directly conjugated to 
HRP.   Second, biotin-tagged molecules are useful in pull-down experiments to assay 
protein-protein interactions by fishing out the biotinylated protein with avidin beads. 
Before metabolically labeling cells with non-natural sugars, we first confirmed 
that the CTX-Clv-Biotin reagent irreversibly blocks thiol-containing Q1/E1 complexes 
and Shaker channels expressed in Xenopus oocytes, and that current is restored upon 
linker cleavage.  We then performed a similar experiment with Xenopus oocytes 
expressing CTX-sensitive, “wild-type” Q1/E1 or  Shaker channels that were incubated 
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with a thiol-modified N-acetylmannosamine derivative.  These channels were irreversibly 
blocked, suggesting that the modified sugars were taken-up, incorporated into the 
extracellular glycans of the proteins, and provided a reactive handle to which the reagent 
could tether.  In all, these results show promising preliminary experiments that the 
tetherered blocker technology discussed in Chapters II and III can be used to label 
channels in native cells. 
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A) 
 
4.1 
 
B) 
 
 
Figure IV-1    Structure of 1,3,4,6-tetra-O-acetyl-2-acetylthioacetamido-2-deoxy-a-
D-mannopyranose 4.1 (Ac5ManNTGc) and metabolic labeling of N-glycosylated cell 
surface proteins. 
 
(A) The thiol containing ManNAc non-natural sugar analog is a thiol containing 
aceylated sialic acid precursor.  (B)  Oocytes fed this sugar will deacylate and incorporate 
it into glycans containing terminal sialic acids, resulting in the expression of reactive 
extracellular thiols (SH), which can be labeled with biotin (B) using CTX-Clv-Biotin. 
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Material and Methods 
 
Mutagenesis and In Vitro Transcription:   
For optimal CTX binding to the Q1/E1 complex, CTX sensitive Q1 (Q1*) and 
hemagglutinin-tagged E1 constructs were used (Chen et al., 2003) and subcloned into a 
pCDNA3.1+ plasmid containing the 5’ and 3’ UTRs from the Xenopus β-globin gene and 
mammalian gene for optimal expression in both Xenopus oocytes and mammalian CHO 
cells.  Shaker constructs were subcloned into a modified pBluescript SK+ vector 
(Statagene) with the 5’ and 3’ UTR from the Xenopus β-globin and mammalian gene for 
optimal expression in oocytes or CHO cells.  Site-directed mutagenesis was performed by 
Quickchange Mutagenesis (Stratagene) using E1 primers described in Chapter II and 
mRNA in vitro run-off transcription was performed by linearizing with MluI (NEB) and 
synthesizing with T7 RNA polymerase (Promega).  
 
Electrophysiology: 
Standard techniques and solutions were used for the preparation of and recording 
from Xenopus oocytes by two-electrode voltage clamp (Rudy and Iverson, 1992) 2–4 d 
after cRNA injection (methods chapter III).  Oocytes expressing KCNE extracellular 
cysteine residues were stored in ND96 bathing solution (96 mM NaCl, 2 mM KCl, 1.8 
mM CaCl2, 5 mM HEPES, pH 7.4, 50 µg mL-1 gentamicin containing 2 mM L-
glutathione (Sigma)) and incubated in ND96 recording (96 mM NaCl, 2 mM KCl, 0.3 
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mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4, containing 1 mM TCEP 
(CalBioChem)) for 10 min prior to recording.  Oocytes were injected with a Q1:E1 
mRNA ratio (15:5 ng) to ensure that E1 was in excess or 5 ng Shaker-IR.  Oocytes were 
incubated for 3–5 days with 3 mM L-glutathione, pre-treated with 1 mM TCEP for 15 
min before recording, and the current was measured by holding at – 80 mV and pulsing 
to +20 mV for 5 s every 30 s.  
 
Cell Surface Chemistries:   
Oocyte labeling: Labeling reagent CTX-Clv-Biotin (10 nM) was in ND96 solution with 
50 µg mL-1 bovine serum albumin and was added to the bath by a gravity-fed perfusion 
system with a chamber clearing time of ~ 10 s. CTX-Clv-Biotin cleavage was 
accomplished by 1 mM TCEP for ~180 s. 
 
Metabolic Labeling with Non-natural Sugars: 
Metabolic labeling of oocytes was performed by evaporating 100 µl of a 10 mM 
solution of Ac5ManNTGc in ethanol onto a 30 mm x 7 mm incubation dish.  
Approximately 30 oocytes in 2 ml ND96 solution (methods chapter II) were added to 
each dish.  The solution in the incubation dish was changed every 24 hr. with freshly 
evaporated Ac5ManNTGc until recordings were performed. 
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Chemical Synthesis: 
 
Non-natural ManNAc synthesis: 
1,3,4,6-tetra-O-acetyl-2-acetylthioacetamido-2-deoxy-a-D-mannopyranose 
(Ac5ManNTGc) 4.1:  Thiol containing non-natural ManNAc sugar synthesis was 
performed according to Yarema, Nature Protocols, Vo1, No. 5, 2006, 2377.  The purified 
product was confirmed by electrospray ionization mass spectrometry (Figure IV-2) and 
was aliquoted, lyophilized, and stored at -20 °C.  For oocytes uptake of Ac5ManNTGc, 
100 ul of a 10 mM solution in ethanol was evaporated onto oocyte incubation dishes. 
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Figure IV-2   Ac5ManNTGc electrospray mass spectrum (positive mode). 
 
Expected MW for Ac5ManNTGc:  +1 486.0 
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Synthesis of cleavable linker precursors and cleavable linker: 
 
Bis(Fmoc-Lysine (Boc)) cystamide (4.2):   A solution of cystamine dihydrochloride 
0.113 mg (0.5 mmol) in 15 mL methanol was added 204 mg (2.0 mmol) of triethylamine 
and Fmoc-Lys(Boc)-OPfp 0.635 g (1.0 mmol) at room temperature. The mixture was 
stirred at room temperature for 12 hours and a jelly-like solid was formed, and 15 mL of 
chloroform was added to make the reaction solution clear.  The mixture was filtered 
through a short silica gel column (3.0 g of silica gel). The solvent was evaporated under 
vacuum to afford a crude product of compound 4.2 as a white solid. This crude product 
was used for next reaction without further purification. 
 
Bis(Lysine-(Boc)) cystamide (4.3):  The crude product of compound 4.2 in 20 mL 
methylene chloride and 1 mL of piperidine was added to the reaction solution. The 
reaction mixture was stirred at room temperature for 12 hours. The mixture was then 
evaporated to dryness to give a yellowish solid. This solid was added extracted with (50 
mLx2) hexane and stirred vigrously by a magnetic stirrer. The supernatant hexanes layer 
was decanted. The solid residue was dissolved in 50 mL chloroform and washed with 15 
mL water. The chloroform layer was dried with anhydrous sodium sulfate and evaporated 
under vacuum to give a white solid crude diamine compound 4.3 (~530 mg). This white 
solid was used for next reaction without further purification.  
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Bis(maleimido-Lysine-(Boc)) cystamide (4.4):  The crude compound 4.3 was dissolved 
in 15 mL DMF and 460 mg (1.7 mmol) of maleimide NHS ester was added to the 
solution. The reaction was stirred for 2 days. Then the solvent was removed under 
vacuum to offer a white solid. The crude product was purified by silica gel 
chromatography eluting with 5:1 CHCl3:MeOH to afford 100 mg compound 4.4 as 
confirmed by NRM (22% for 3 steps).   
 
Bis(maleimido-lysine) cytamide (4.5):  100 mg of compound 4.4 (0.11 mmol) was added 
with a solution of 30 mL TFA, 30 mL CHCl3 and 300 uL of water. This reaction mixture 
was stirred at room temperature for 5 hours and then the solvents were removed under 
vacuum to offer a white solid. The white solid was dissolved in 10 mL water and 10 mL 
CHCl3 and stirred vigorously. The aqueous layer was separated and washed by 5 mL 
CHCl3 again. The aqueous layer was then evaporated to give a white solid crude product 
4.5, as confirmed by NMR. 
 
Bis(maleimido-lysine-biotin) cytamide (4.6):  Crude product 4.5 was dissolved in 6 mL 
DMF and  81 mg of Biotin-NHS ester (0.24 mmol) and 29 mg Et3N (0.29 mmol) were 
added. The reaction mixture was stirred at room temperature for 2 days. The solvent was 
removed under vacuum. The crude product was dissolved in 10 mL CHCl3 and 10 mL 
water. The mixture was stirred vigrously for 20 min. Some solid did not go into either 
chloroform layer or aqueous layer. The solid was collected and dried under vacuum for 
12 hours to give a solid 38 mg of cleavable bismaleimide 4.6 (0.036 mmol, 32% from 
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compound 4.4).  Product was confirmed by ESI-MS, 1H NMR (400 MHz, CDCl3) δ 1.10-
1.70 (m, 4 H), 2.02 (m, 4 H), 2.38 (m, 4 H), 2.54 (m, 2 H), 2.60-2.80 (m, 8 H), 2.96 (m, 4 
H), 3.09 (m, 2 H), 3.57 (m, 4 H), 4.10 (m, 4 H), 4.28 (m, 2 H), 6.35 (s, 2 H), 6.41 (s, 2 H), 
6.98 (s, 4 H), 7.73 (m, 2H), 8.06 ( m, 4 H).   
 
 
CTX-Clv-Biotin Derivatization: 
 
Recombinant CTX R19C was purified and the protected CTX-MTSET adduct 
was prepared according to Shimony et al. (Shimony et al., 1994). CTX-Lclv-Biotin was 
synthesized as follows: 16 nmol of CTX-MTSET in 2 mL of Buffer C (10 mM NaCl, 10 
mM KPi, pH 7.4) was reduced with 1 mM DTT for 30 min and bound to a SP Sephedex 
(Sigma) cation exchange column. DTT was washed from the column using 150 mL of 
Buffer C, and the resin bound CTX was labeled with 3 mL of 5 mM Lclv-biotin in Buffer 
C with a final acetonitrile concentration of 5%. After 10 min, the column was washed 
with Buffer C to remove excess label, and CTX-Lclv-Biotin was eluted with 1 M NaCl in 
10 mM KPi, pH 7.4.  CTX-Lclv-Biotin (Figure IV-6) was desalted and HPLC purified 
using a C18 column (4.6 mm x 250 mm) eluting with solvent A (0.1% TFA)/solvent B 
(acetonitrile) gradient 10% to 40% B over 30 min. The concentration of purified CTX-
Lclv-Biotin was determined by UV spectrometry (OD280 of 1.0 = 100 µM CTX (Shimony 
et al., 1994)) and labeling efficiency of CTX-R19C was determined to be 35% ± 5% (n = 
10). The purified product was confirmed by electrospray ionization mass spectrometry 
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(Figure IV-3) and was aliquoted, lyophilized, and stored at -20 °C. Individual aliquots 
were resuspended in recording solutions immediately prior to use. 
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Figure IV-3   CTX-Clv-Biotin electrospray mass spectrum (positive mode). 
 
Expected MW for CTX-Clv-Biotin:  4660.0 (methionine oxidized);  +4, 1164.0; +7, 
658.0.   
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Results 
 
To label thiol-containing Shaker α- and E1 β-subunits with biotin the reagent 
CTX-Lclv-Biotin was created.  This reagent consists of the K+ channel blocking toxin 
charybdotoxin coupled to two molecules of biotin through a cleavable thiol reactive 
linker (Figure IV-6).  The CTX portion of the reagent specifically delivers biotin to 
channels that bind CTX with high affinity, allowing the labeling reaction to be performed 
using nanomolar concentrations of the reagent.  Considering the duration of the labeling 
reaction (mins.) using nanomolar concentrations of reagent, the non-toxin aided 
bimolecular reaction between the reagent and free thiol is inconsequential (less than 1%).  
Therefore, global labeling of all free thiols on the cell surface with biotin is prevented.  
As with the other previously described CTX-derivatives, once bound CTX-Clv-Biotin 
tethers to channels through a maleimide thiolate linkage resulting in irreversible channel 
block.  Upon TCEP cleavage of the linker region, CTX and one molecule of biotin is 
washed out, while the other biotin molecule permanently labels the channel (Figure IV-
1b).  The CTX-Clv-Biotin reagent was created by reacting excess 4.7 with CTX-R19C.  
Compound 4.7 was synthesized by coupling 2 equivalents of commercially available 
Fmoc-Lys-(Boc)-OPfp with one equivalent of cystamine dihydrochloride in chloroform.  
The mixture was run over a silica column and solvents were evaporated in vacuo to 
afford compound 4.2.  The Fmoc protecting groups on compound 4.2 were selectively 
removed with piperidine to give diamine 4.3.  Two equivalents of maleimide NHS ester 
were coupled to one equivalent of diamine 4.3 using standard activated ester-amine 
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coupling chemistries.  Solvents were removed under vacuum and the remaining white 
solid, compound 4.4, was purified by silica gel chromatography (yield 22% for the three 
steps) (Figure IV-4).    
The Boc protecting groups on compound 4.4 were removed using trifluoroacetic 
acid and water, and the solvents were removed under vacuum to give product 4.5 .  
Commercially available Biotin-NHS was dissolved in DMF and triethylamine and added 
to crude 4.5.  After two days, the solvents were removed and the product was extracted.  
A solid that did not dissolve in either layer was collected and dried under vacuum to give 
the biotin-bismaleimide, 4.6 (32% yield from last 2 steps) (Figure IV-5). CTX-Clv-Biotin 
was then synthesized by adding 100-fold molar excess of 4.6 to reduced CTX R19C, 
(Figure IV-6 bottom) and HPLC purified (see Methods section for details). 
Before metabolically labeling with non-natural sugars, I first determined whether 
the CTX-Clv-Biotin reagent irreversibly blocks thiol-containing Q1/E1 complexes and 
Shaker channels, and upon linker cleavage current is restored.  To do this we utilized the 
cysteine in Q1/E1T14C, which was modifiable using linkers of similar length and structure 
(Morin and Kobertz, 2007, Morin and Kobertz, 2008).  TEVC recordings show that 
Q1/E1T14C complexes are irreversibly blocked when exposed to this reagent, but upon 
treatment with 1 mM TCEP current is restored to original levels (Figure IV-7 top).  This 
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Figure IV-5.  Chemical synthesis of compound 4.6. 
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Figure IV-6.  Structure of Clv-Biotin 4.6 and synthesis of CTX-Clv-Biotin 
 
(Top)  The Clv-Biotin reagent 4.6 consists of three main components, a cleavable 
disulfide bond, 2 biotin moieties and 2 thiol reactive maleimides.  (Bottom)  CTX-
MTSET is reduced and reacted with excess 4.6 to create reagent CTX-Clv-Biotin. 
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indicates that the reagent is able to block and tether to channels, creating irreversible 
block, but upon chemical treatment the blocking moiety is liberated and presumably the 
channels are now labeled with biotin.  Control experiments using E1 peptides lacking the 
exogenous cysteine showed CTX-Lclv-Biotin is unable to tether and therefore labeling is 
dependent on the cysteine introduced through mutagenesis (Figure IV-7 middle).  
Consistent with the other CTX derivatives, labeling was dependent on first binding to the 
channels, as labeling was prevented when CTX-Lclv-Biotin was competitively inhibited 
with excess CTX (Figure IV-7bottom). 
Biotin labeling was not limited to the KCNE β-subunits, as Shaker channel α-subunits 
harboring a Q350C mutation, an extracellular position within Shaker that is less than 20 
angstroms from the pore (Blaustein et al., 2000), were also irreversibly blocked by CTX-
Lclv-Biotin.  These channels were ~80% irreversibly blocked, as ~20% of the current 
returned upon reagent washout.  Again, irreversible block could be reversed with mild 
reductant (Figure IV-8a).  Control experiments using Shaker subunits lacking the 
exogenous cysteine showed CTX-Lclv-Biotin is unable to tether and therefore labeling is 
dependent on the cysteine introduced through mutagenesis (Figure IV-8b).  Again 
labeling was dependent on first binding to the channels as irreversible block was 
prevented when CTX-Lclv-Biotin was competitively inhibited with excess CTX  (Figure 
IV-8c). 
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Figure IV-7.  Characterization of CTX-Clv-Biotin on KCNQ1/KCNE complexes.   
 
Top-bottom) (Left) Overlays of the total current elicited by a 20 mV pulse from a   -80 
mV holding potential from oocytes expressing Q1/E1 complexes.  Scale bars are 0.5 µA 
and 0.5 s.  (Right) Normalized CTX-sensitive current (I/Imax).  Oocytes were 
depolarized every 30 s and the data points were obtained at the end of a 5 s pulse.  Gray 
and red data points correspond to the raw traces on the left.   
 
Top)  Q1/E1T14C complexes are irreversibly blocked by CTX-Clv-Biotin.  Q1/E1T14C 
complexes were treated with 10 nM CTX-Clv, followed by washout and 1 mM TCEP 
treatment, demonstrating the ability of the reagent to label these complexes with biotin 
from delivered by CTX-Clv-Biotin.   
 
Middle) Q1/E1 WT complexes are reversibly blocked by CTX-Clv-Biotin.  
Complexes were treated with 10 nM CTX-Clv, followed by washout, demonstrating the 
necessity of the cysteine residue for labeling to occur. 
 
Bottom)  Competitively inhibited Q1/E1T14C are reversibly blocked by CTX-Clv-
Biotin. Complexes were treated with 500 nM CTX and 10 nM CTX-Clv, followed by 
washout, demonstrating the need to first bind to the channel for biotin labeling to occur. 
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As discussed, the ultimate goal is to develop a technique to label native channels 
through the incorporation of non-native thiol containing sialic acids into the extracellular 
N-linked glycans of theses proteins.  Aceylated thiol-containing ManNAc, a sialic acid 
precursor (Figure IV-1a) was synthesized (Synthesis) and Q1/E1 expressing oocytes 
were incubated with 10 µM thiol-sugar 4.1 for 3 days.  To determine whether E1 β-
subunits incorporated the unnatural glycans, the oocytes were treated with CTX-Mal, 
which irreversibly blocks Q1/E1 currents  (Figure IV-9 top).  Control experiments in 
which the modified sugar was absent from the media afforded the same amount of block, 
but was 100% reversible, showing the dependence of the labeling reaction on the sugar 
delivered thiol (Figure II-6b and Figure III-5a).  A second control experiment showed 
irreversible block is dependent on an N-linked glycoslylated E1 peptide, because when 
assaying Q1 channels alone, which are not N-linked glycoslylated, only reversible block 
is seen with CTX-Mal (Figure IV-9 bottom). 
The metabolically labeling experiment was repeated using oocytes expressing WT 
Shaker channels to demonstrate that tethering can occur through N-linked glycosylated α-
subunits (Figure IV-10).  WT Shaker channels incubated with the non-natural sialic acid 
precursor were irreversibly blocked by CTX-Mal whereas when the modified sugar was 
absent from the media the block was 100% reversible, showing the dependence of the 
labeling reaction on the sugar supplied thiol (Figure IV-8 bottom).  Table IV-2 shows 
CTX-Clv-Biotin off rates are comparable to the other CTX-derivatives dissociating from 
Q1/KCNE complexes.  Shaker channels have a greater affinity for charybdotoxin than 
Q1/KCNE complexes which slows the dissociation kinetics.
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Figure IV-8.  Characterization of CTX-Clv-Biotin on Shaker channels  
 
(Top-bottom) Overlays of the total current elicited by a 20 mV pulse from oocytes 
expressing Shaker channels.   Scale bars are 0.5 µA and 0.5 ms.  (Right) Normalized 
CTX-sensitive current (I/Imax).  Oocytes were depolarized every 10 s and the data points 
were obtained at the end of a 500 ms pulse.  Gray and red data points correspond to the 
raw traces on the left.   
 
(Top)  Shaker Q350C complexes are irreversible blocked by CTX-Clv-Biotin.  
Shaker Q350C channels were treated with 10 nM CTX-Clv-biotin, followed by washout 
and 1 mM TCEP treatment, demonstrating the ability of the reagent to irreversibly block 
channel, and label these channles with biotin upon release.   
 
 
(Middle) Competitively inhibited Shaker channels are reversibly blocked by CTX-
Clv-Biotin.  Complexes were treated with 500 nM CTX and 10 nM CTX-Clv-Biotin, 
followed by washout, demonstrating the need to bind to the channel to react with the free 
thiol and tether.   
 
(Bottom)  Competitively inhibited Shaker 350C and Shaker (wild type) complexes 
are reversibly blocked by CTX-Clv-Biotin.  Complexes were treated with 10 nM CTX-
Clv-Biotin, followed by washout, demonstrating the necessity of the cysteine residue for 
labeling to occur 
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Figure IV-9.  Q1/E1WT complexes are irreversibly blocked by CTX-Mal when fed 
thiolated sialic acid, Q1 only channels are reversibly blocked.  
 
(Left) Overlays of the total current elicited by a 20 mV pulse from oocytes expressing 
Q1/E1 WT (top) or  Q1 only(bottom).  Scale bars are 0.5 µA and 0.5 s.  (Right) 
Normalized CTX-sensitive current (I/Imax).  Oocytes were depolarized every 30 s and 
the data points were obtained at the end of a 5 s pulse.  Gray and red data points 
correspond to the raw traces on the left.  (Top)  Acetylated thiol-MaNAc fed Q1/E1 
complexes were treated with 10 nM CTX-Mal, followed by washout.  Irreversible block 
demonstrates the non-natural sugar is displayed on the cell surface de-aceylated.  
(Bottom)  Aceylated thiol-MaNAc fed Q1 only channels are irreversibly block by 10 nM 
CTX-Mal, demonstrating the requirement of E1 in this assay.  
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Figure IV-10.  Shaker channels are irreversibly blocked by CTX-Mal when fed 
acetylated thiol-MaNAc.  
 
(Left) Overlays of the total current elicited by a 20 mV pulse from oocytes expressing 
Shaker channels.  Scale bars are 0.5 µA and 0.5 ms.  (Right) Normalized CTX-sensitive 
current (I/Imax).  Oocytes were depolarized every 10 s and the data points were obtained 
at the end of a 500 ms pulse.  Gray and red data points correspond to the raw traces on 
the left.  Shaker complexes were irreversibly blocked  with 10 nM CTX-Mal 
demonstrating labeling can occur through thiol containing non-natural sugars. 
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Table IV-1.  Recovery parameters after CTX-Clv application1 
Construct Treatment τrecovery (s) % recovery n 
Q1/E1 CTX-Clv 98  ± 1 95  ± 2? 5 
Q1/E1T14C CTX-Clv, TCEP 97  ± 1 96  ± 2 4 
Q1/E1T14C CTX-Clv + excess CTX     155  ± 4  96  ± 1 3 
Q1/E1T14C 
CTX-Clv, CTX-Mal, 
TCEP 94  ± 3 94  ± 1 3 
Q1/E1T14C CTX-Clv-Biotin 125 ± 5 96  ± 2 3 
Shaker (Q350C) CTX-Clv-Biotin 540 ± 12 98  ± 4 3 
     
 
1Data are from individual experiments obtained from 3–5 oocytes.  Treatment 
describes the sequential application of chemical reagents to the indicated construct.  
Time constants of recovery were fit to a single exponential as described in Material 
and Methods.  Percent recovery is a comparison between the amount of current 
remaining after CTX-Clv release to the amount of current before CTX-Clv 
application.   Values are mean ± SEM. 
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Discussion 
 
A cleavable tethered blocker reagent was developed to label K+ channel subunits 
with biotin.  Q1/E1T14C complexes were irreversibly blocked upon exposure to the CTX-
Clv-Biotin reagent, and current fully returned after TCEP induced linker cleavage (Figure 
IV-7a).  Control experiments show this reaction is dependent on the mutated cysteine in 
the E1 peptide and the reagent must bind to the channel for labeling to occur (Figure IV-
7b and c).  Based on the design of the reagent, the channels are now presumably labeled 
with biotin.  Western blotting of total cell surface proteins for biotin will confirm that 
indeed E1 is modified with biotin and this was specific, i.e. CTX was able to deliver the 
label to E1 peptides only and other thiol containing cell surface protein were not labeled. 
This experiment is currently being performed, along with appropriate controls, using 
mammalian CHO K-1 cells expressing Q1/E1T14C complexes. 
The ability to use this labeling strategy in native cells to probe endogenous 
channels was realized by using a thiol-containing non-natural ManNAc derivative.  
Oocytes expressing “wild-type” Q1/E1 complexes incubated with this sugar were 
irreversibly blocked when exposed to the non-cleavable CTX-Mal reagent.  The control 
experiments showed that this block was “sugar fed” dependent and require the proteins to 
be N-glycosylated (figure IV-9).  This shows that oocytes are able to take-up, deacetylate, 
and incorporate this sialic acid precursor into N-linked glycans as they would native 
sialic acid.  The CTX-Mal reagent does not contain the biotin label, but these results 
along with those discussed above (Figure IV-7) indicate that exposure of “sugar-fed” 
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channels to CTX-Clv-Biotin would result in biotin labeled channels via the sugar moiety.  
Again, Western blot analysis probing for biotin would reveal specific labeling of E1 
peptides.     
Consistent with experiments using other CTX derivatives, CTX-Lclv-Biotin does 
not afford 100% block of Q1E1 channels, likely due to non-CTX sensitive endogenous 
Q1 channels native to the oocyte partnering with E1 peptides to afford non-blockable IKs 
like current. 
Electrophysiological experiments demonstrated that not only β, but Shaker 
channel α-subunits can also be labeled with biotin.  Like Q1/E1 complexes, cells  
expressing Shaker (Q350C) channels or wild-type Shaker channels fed thiol-containing 
MaNAc, were irreversibly blocked by the CTX-Clv-Biotin or CTX-Mal reagent (Figure 
IV-8 and IV-10).  Control experiments showed that when Shaker lacked an exogenous 
cysteine or was not sugar-fed block was completely reversible, demonstrating a free thiol 
is required for tethering the reagent to the channel.  As with Q1/E1 complexes, Western 
blot analysis will conclusively demonstrate biotin labeling and that it is specific, i.e. the 
bimolecular reaction between the reagent and thiol (sugar or cysteine) occurs more 
slowly than the duration of the labeling experiment. 
When using Shaker Q350C we do see a small level of reversibility upon reagent 
washout, possibly because the target cycteine (Q350C) in Shaker is not in an ideal 
location for tethering.  The cysteine might be sterically blocked by other channel residues 
or only within reach when the linker is at its most extended conformation.  With enough 
site directed mutagenesis a residue location that affords 100% irreversible block maybe 
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found.  However, for the scope of these labeling experiments, 100% irreversible block is 
not a necessity.  All that is needed is a high percentage of labeling at the cell surface for 
biochemical studies.   
Contrary to the tethering experiments using Shaker channels with exogenous 
cysteines, irreversible block of Shaker channels was 100% when tethering through thiol 
containing glycans.  This may happen because N-linked glycans have 3-5 sialic acid 
terminal sugars, thereby increasing the number of reactive thiols in the outer vestibule 5 
fold, from 4 to 20, and therefore enabling more efficient tethering.  Of note is that CTX-
Clv-Biotin does block 100 % of the current in the experiments using Shaker channels, 
which do not comingle with oocyte endogenous Q1, and therefore all Shaker complexes 
are blockable. 
Taken together, these results show a novel approach to labeling specific cell 
surface proteins and not all of proteins at the cell surface capable of being modified, i.e. 
any cell surface expressed protein with reduced thiols.  This chapter discussed labeling 
with biotin, useful in pull down experiments to, for example, quantify a cell surface 
population or investigate interacting protein partners.  To expand the experimental 
repertoire, the biotin moiety can easily be replaced by other functional groups, e.g. 
fluorophores, which would prove useful in FRET or trafficking experiments.  
Additionally, this chapter provides evidence that by growing cells on modified sugars the 
tethered blocker technology is compatible with WT channels and can be used to study 
channels in native tissues.  This will provide a powerful tool to overcome one of the 
greatest hurdles in the ion channel field: assaying channels in their natural environment.  
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Chapter V: Future Directions 
 
The results presented in Chapter II, which show two KCNE subunits per Q1/E1 
complex, produce a number of questions concerning channel assembly, complex structure, 
and drug development.  First, two KCNE beta-subunits per complex lend credence to the 
notion that these complexes assemble in the ER (Chandrasekhar et al., 2006) as dimers of 
dimers (Tu and Deutsch, 1999; Lu et al., 2007).  This idea suggests that a KCNE subunit 
may bifurcate two Q1 alpha-subunits, acting as protinaceous glue that holds them 
together until fully assembled tetramers are formed and trafficked to the cell surface.  
Pulse chase labeling experiments may be able to differentiate between a dimer of dimers 
assembly scenario from assembled Q1 tetramers incorporating E1 peptides, one at a time 
or two simultaneously.  Imaging radioactive gels would show assembling complexes, if 
E1 peptides join already assembled tetramers, a Q1x4 + E1x1 complex would be evident.  
If assembly occurs through a dimer of dimers, Q1x2 + E1x1 complexes would be seen.  
Given that the length of the shortest tethering linker was 20 angstroms, it suggests that 
the KCNE peptides reside no more than ~20 angstroms from the pore, perhaps 
positioning KCNE subunits in the cleft formed between subunits.  This would allow the 
KCNE peptide to essentially line the pore, as suggested (Sesti et al., 2000; Tai and 
Goldstein, 1998; Tai et al., 1997) .  Recent work has shown that the N-terminus of E1 
contains two alpha helicies separated by a  flexible region (Congbao Kang et al., 2008).  
It is therefore possible that the transmembrane region of E1 is farther than 20 angstroms 
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from the pore, but the N-terminal cysteine is modifiable because the N-terminus kinks 
closer to the ion conduction pathway.  Furthermore, the 4:2 α:β stoichiometry provides a 
unique architectural scaffold on which to base the design of pharmacological agents that 
would target these channels. 
The results in Chapter III, heteromeric complexes, generate the possibility that the 
well studied and well-defined cardiac IKs current is not only generated by Q1/E1 
complexes, but Q1/E1/E4 complexes as well.  The results show virtually no change in 
opening and closing channel kinetics and a slight change in the voltage dependence when 
E4 is present in the complex, which would allow the macroscopic current through these 
channels to be fine-tuned quickly to deal with cardiac stresses.  At the very least, E4 may 
act as a structural surrogate, allowing the expression of fully formed functional 
complexes even when E1 is limiting.  This idea is not all that far fetched given E4 is the 
most abundant KCNE mRNA transcript in the heart.  A most pressing question that 
requires further study is how cells prevent deleterious complex assembly, as E3 is also 
expressed in the heart, but would generate a detrimental leak channel if complexed with 
Q1 (or Q1/E1).  Perhaps E3 mRNA transcripts are degraded before protein translation, 
E3 partners with a channel other than Q1, or yet unknown cellular mechanism prevent 
Q1/E3 channel assembly.  The CTX-Mal reagent could also be used to disentangle the 
phenotypic effects of KCNE mutations on assembly from those on modulation by 
deconvolving the functional contributions of unpartnered Q1 channels and mutant Q1–
KCNE complexes. 
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Chapter IV discusses labeling specific cell surface proteins with experimentally 
useful tags.  Biotin was used to show proof of principle, but the modular design of the 
cleavable linker allows it to easily incorporate other molecular entities, such as 
fluorophores that would be useful in monitoring recycling rates, degradation, or 
measuring distances between β-subunits using FRET experiments. 
The fact that cells take-up and incorporate non-natural sugar derivatives into their 
extracellular glycans allows endogenous channels to display useful reactive handles.  The 
use of non-natural thiol-containing-sugars allows the technology to be used in native cells, 
not only with ion channels, but any cell surface protein that is N-linked glycosylated and 
capable of binding a molecule (protein or synthetic compound) with high affinity.  This 
would include transporters, notoriously difficult to study due to their complex function 
and membrane embedded structure.  The questions that were answered in Chapters II and 
III could be reexamined in native cells using metabolical thiol incorporation.  
Furthermore, investigating the ability of Long QT causing mutants to assemble into 
complexes in native cells would be of significant medical relevance.   
Finally, all tethering displayed in this thesis involved maleimides reacting with 
free thiols.  It has been shown that similar tethering strategies using other chemistries 
work equally as well, such as directing a nucleophile toward an electrophiles (Fortin et al., 
2008), or “click” chemistry between an alkyne and azide (Laughlin and Bertozzi, 2007).  
Give the modularity of the reagents used in this thesis, these different chemistries should 
be equally compatible. 
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In conclusion, this thesis demonstrates the importance of combining the 
perspectives and technical attributes on two scientific disciplines, biology and chemistry, 
to answer physiologically relevant questions.   
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